A disease of the CARDIAC MUSCLE developed subsequent to the initial protozoan infection by TRYPANOSOMA CRUZI. After infection, less than 10% develop acute illness such as MYOCARDITIS (mostly in children). The disease then enters a latent phase without clinical symptoms until about 20 years later. Myocardial symptoms of advanced CHAGAS DISEASE include conduction defects (HEART BLOCK) and CARDIOMEGALY.
The agent of South American trypanosomiasis or CHAGAS DISEASE. Its vertebrate hosts are man and various domestic and wild animals. Insects of several species are vectors.
Diseases that do not exhibit symptoms.
A form of CARDIAC MUSCLE disease that is characterized by ventricular dilation, VENTRICULAR DYSFUNCTION, and HEART FAILURE. Risk factors include SMOKING; ALCOHOL DRINKING; HYPERTENSION; INFECTION; PREGNANCY; and mutations in the LMNA gene encoding LAMIN TYPE A, a NUCLEAR LAMINA protein.
A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).
A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
A form of CARDIAC MUSCLE disease in which the ventricular walls are excessively rigid, impeding ventricular filling. It is marked by reduced diastolic volume of either or both ventricles but normal or nearly normal systolic function. It may be idiopathic or associated with other diseases (ENDOMYOCARDIAL FIBROSIS or AMYLOIDOSIS) causing interstitial fibrosis.
A transient left ventricular apical dysfunction or ballooning accompanied by electrocardiographic (ECG) T wave inversions. This abnormality is associated with high levels of CATECHOLAMINES, either administered or endogenously secreted from a tumor or during extreme stress.
A genus of the subfamily TRIATOMINAE. Several species are vectors of TRYPANOSOMA CRUZI.
Documents describing a medical treatment or research project, including proposed procedures, risks, and alternatives, that are to be signed by an individual, or the individual's proxy, to indicate his/her understanding of the document and a willingness to undergo the treatment or to participate in the research.
A group of fatty acids, often of marine origin, which have the first unsaturated bond in the third position from the omega carbon. These fatty acids are believed to reduce serum triglycerides, prevent insulin resistance, improve lipid profile, prolong bleeding times, reduce platelet counts, and decrease platelet adhesiveness.
Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.
The branch of medicine concerned with diseases, mainly of parasitic origin, common in tropical and subtropical regions.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY.
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
The hollow, muscular organ that maintains the circulation of the blood.
A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.
Diagnostic procedures, such as laboratory tests and x-rays, routinely performed on all individuals or specified categories of individuals in a specified situation, e.g., patients being admitted to the hospital. These include routine tests administered to neonates.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues. The standard approach is transthoracic.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
Inflammatory processes of the muscular walls of the heart (MYOCARDIUM) which result in injury to the cardiac muscle cells (MYOCYTES, CARDIAC). Manifestations range from subclinical to sudden death (DEATH, SUDDEN). Myocarditis in association with cardiac dysfunction is classified as inflammatory CARDIOMYOPATHY usually caused by INFECTION, autoimmune diseases, or responses to toxic substances. Myocarditis is also a common cause of DILATED CARDIOMYOPATHY and other cardiomyopathies.
Agents destructive to the protozoal organisms belonging to the suborder TRYPANOSOMATINA.
The structure of one molecule that imitates or simulates the structure of a different molecule.
Process whereby the immune system reacts against the body's own tissues. Autoimmunity may produce or be caused by AUTOIMMUNE DISEASES.

Alterations in cardiac beta-adrenergic receptors in chagasic mice and their association with circulating beta-adrenoceptor-related autoantibodies. (1/382)

OBJECTIVE: Cardiac tissue from chagasic mice was studied to evaluate the expression and biological activity of beta-adrenoceptors in association with circulating beta-adrenoceptor-related autoantibodies. METHODS: BALB/c inbred mice that were either treated or not treated with atenolol (2.5 mg/kg) and infected or not infected with 1 x 10(4) trypomastigotes (CA-1 strain) were sacrificed weekly up to week nine. Morphological, binding and contractility studies were performed on the four different groups of animals. The effect of their serum antibodies was also assayed in binding and contractility studies on normal heart preparations. RESULTS: Hearts from chagasic myocarditis mice showed a beta-adrenoceptor-related dysfunction, with a decrease in heart contractility, impaired response to exogenous beta-adrenoceptor agonist and a significant reduction in beta-adrenergic binding sites. Those effects were maximum at eight-nine weeks post-infection and were improved by treating infected mice with atenolol. In addition, serum or IgG from chagasic myocarditis mice was capable of interacting with cardiac beta-adrenoceptors, reducing the number of binding sites and inhibiting the contractile response to exogenous norepinephrine. IgG effects that were observed in normal myocardium, were highest in sera from mice eight-nine weeks post-infection and correlate with the degree of myocarditis. Moreover, chagasic autoantibodies from infected mice recognized a peptide corresponding to the sequence of the second extracellular loop of the human beta 1-adrenoceptor. CONCLUSIONS: (1) The development of alterations in beta-adrenergic receptors, related to cardiac dysfunction, may be associated with the presence of circulating antibodies against these receptors and (2) it is possible that the chronic deposits of these autoantibodies in cardiac beta-adrenoceptors could lead to a progressive blockade with sympathetic denervation, a phenomenon that has been described in the course of chagasic myocarditis.  (+info)

Myocardial parasite persistence in chronic chagasic patients. (2/382)

The persistence of Trypanosoma cruzi tissue forms was detected in the myocardium of seropositive individuals clinically diagnosed as chronic chagasic patients following endomyocardial biopsies (EMBs) processed by immunohistochemical (peroxidase-anti-peroxidase [PAP] staining) and molecular (polymerase chain reaction [PCR]) techniques. An indirect immunofluorescent technique revealed antigenic deposits in the cardiac tissue in 24 (88.9%) of 27 patients. Persistent T. cruzi amastigotes were detected by PAP staining in the myocardium of 22 (84.6%) of 26 patients. This finding was confirmed with a PCR assay specific for T. cruzi in 21 (91.3%) of 23 biopsy specimens from the same patients. Statistical analysis revealed substantial agreement between PCR and PAP techniques (k = 0.68) and the PCR and any serologic test (k = 0.77). The histopathologic study of EMB specimens from these patients revealed necrosis, inflammatory infiltrates, and fibrosis, and made it possible to detect heart abnormalities not detected by electrocardiogram and/or cineventriculogram. These indications of myocarditis were supported by the detection of T. cruzi amastigotes by the PAP technique or its genome by PCR. They suggest that although the number of parasites is low in patients with chronic Chagas' disease, their potential for heart damage may be comparable with those present during the acute phase. The urgent necessity for testing new drugs with long-term effects on T. cruzi is discussed in the context of the present results.  (+info)

Parasite persistence correlates with disease severity and localization in chronic Chagas' disease. (3/382)

The protozoan parasite Trypanosoma cruzi infects up to 20 million people in Latin America, and the resulting disease (Chagas' disease) is a leading cause of heart disease and death in young adults in areas endemic for the parasite. The clinical symptoms of Chagas' disease have been attributed to autoimmune reactivity to antigens shared by the parasite and host muscle or neuronal tissue. In the present study, in situ polymerase chain reaction analysis was used in murine models of Chagas' disease to demonstrate an absolute correlation between the persistence of parasites and the presence of disease in muscle tissue. Clearance of parasites from tissues, presumably by immunologic mechanisms, correlated with the abatement of inflammatory responses and the resolution of disease. These data provide strong evidence for parasite persistence as a primary cause of Chagas' disease and argue for efforts to eliminate T. cruzi from the host as a means for prevention and treatment of Chagas' disease.  (+info)

Cardiac M(2) muscarinic cholinoceptor activation by human chagasic autoantibodies: association with bradycardia. (4/382)

OBJECTIVE: To assess whether exposure of cardiac muscarinic acetylcholine receptors (mAChR) to activating chagasic antimyocardial immunoglobulins results in bradycardia and other dysautonomic symptoms associated with the regulation of heart rate. METHODS: Trypanosoma cruzi infected patients with bradycardia and other abnormalities in tests of the autonomic nervous system were studied and compared with normal subjects. Antipeptide antibodies in serum were demonstrated by an enzyme linked immunosorbent assay using a synthetic 24-mer-peptide corresponding antigenically to the second extracellular loop of the human heart M(2) mAChR. The functional effect of affinity purified antipeptide IgG from chagasic patients on spontaneous beating frequency and cAMP production of isolated normal rat atria was studied. RESULTS: There was a strong association between the finding of antipeptide antibodies in chagasic patients and the presence of basal bradycardia and an altered Valsalva manoeuvre (basal bradycardia: chi(2) = 37.5, p < 0. 00001; Valsalva manoeuvre: chi(2) = 70.0, p < 0.00001). The antipeptide autoantibodies also showed agonist activity, decreasing the rate of contraction and cAMP production. The effects on rat atria resembled the effects of the authentic agonist and those of the total polyclonal chagasic IgG, being selectively blunted by atropine and AF-DX 116, and neutralised by the synthetic peptide corresponding in amino acid sequence to the second extracellular loop of the human M(2) mAChR. CONCLUSIONS: There is an association between circulating antipeptide autoantibodies in chagasic patients and the presence of bradycardia and other dysautonomic symptoms. Thus these autoantibodies are a marker of autoimmune cardiac autonomic dysfunction. The results support the hypothesis that autoimmune mechanisms play a role in the pathogenesis of chagasic cardioneuromyopathy.  (+info)

Different microcirculatory and interstitial matrix patterns in idiopathic dilated cardiomyopathy and Chagas' disease: a three dimensional confocal microscopy study. (5/382)

OBJECTIVE: To analyse the morphological aspects of the extracellular matrix and microcirculation to clarify whether chronic Chagas' cardiopathy (CCC) is an accurate model to study the pathogenesis of idiopathic dilated cardiomyopathy (IDCM). DESIGN: Thick histological myocardial sections were prepared to analyse collagen, and microcirculation was examined during confocal laser and light microscopy. SETTING: The specimens were prepared at the pathology service of the Heart Institute of Sao Paulo, Brazil. PATIENTS: Nine control hearts, eight IDCM hearts, and 10 CCC hearts were studied after necropsy. MAIN OUTCOME MEASURES: The number of collagen struts per 100x field, the area of fibrosis (%), and the diameters of arterioles and capillaries were measured in each heart to establish outcome. RESULTS: A smaller number (mean (SD)) of collagen struts was seen in the hearts in the IDCM group (9.1 (4.1)) than in the control (22.4 (3.2)) (p < 0.05) or CCC (15.7 (7.4)) (p > 0.05) groups. Fibrosis was greater in the CCC hearts (13.8 (10.5)%) than in the IDCM hearts (5.9 (6.6)%) (p > 0.05). Major increases in arteriole (65.4 (9.9) microm) and capillary (9.9 (1.7) microm) diameters were seen in the CCC hearts but not in the IDCM hearts (arteriole diameter 40.3 (7.9) microm; capillary diameter 7.9 (1.3) microm). CONCLUSIONS: Hearts demonstrating CCC and IDCM present different extracellular and microvessel alterations. This suggests that distinct pathogenic mechanisms are responsible for each condition and that CCC is not an effective model to study IDCM.  (+info)

Application of cardiac gated magnetic resonance imaging in murine Chagas' disease. (6/382)

To evaluate the role of gated cardiac magnetic imaging resonance (MRI) in Chagas' disease, we infected mice with Trypanosoma cruzi (Brazil strain). Two models were chosen for study, the CD1 and the inducible nitric oxide synthase knockout (NOS2-/-) mice. Infection of CD1 mice was associated with a significant increase in the right ventricular inner diameter (RVID) that was reversed in some mice by verapamil. Expression of cardiac NOS2 has been associated with myocardial dysfunction. Therefore, we evaluated chagasic cardiomyopathy in NOS2-/- and syngeneic wild type (WT) mice. Infected WT mice exhibited an increase in RVID in the acute phase (< 60 days postinfection) that was more marked during chronic infection (>100 days postinfection). Chronically infected NOS2-/- mice had an increase in RVID. The RVID in infected WT mice was greater than in NOS2-/- mice. These data demonstrate that MRI is a useful tool in the serial evaluation of the heart in murine Chagas' disease. In addition, it supports the notion that the NOS2-/-/NO pathway may contribute to the pathogenesis of murine chagasic cardiomyopathy.  (+info)

Chronic Chagas' heart disease in a Japanese-Brazilian traveler. A case report. (7/382)

A 57-year-old Japanese-Brazilian man, visiting Japan for only 9 days, was admitted to our hospital due to syncope and frequent ventricular premature beats. He grew up in a rural area of Brazil and moved to Sao Paulo in 1959 when he was 20 years old. We suspected chronic Chagas' heart disease, i.e., dilated cardiomyopathy with apical ventricular aneurysm, right bundle branch block with left anterior fascicular block, and various arrhythmias including supraventricular premature beats, ventricular premature beats and non-sustained ventricular tachycardia because he showed typical echo- and electrocardiographic features of the disease. Coronary arteriograms were normal, and left ventriculogram confirmed the existence of apical ventricular aneurysm. A left ventricle biopsy specimen showed hypertrophic cardiac muscle with mild fibrosis. The diagnosis of chronic Chagas' disease was finally confirmed by the demonstration of Trypanosoma cruzi itself in the blood as well as Trypanosoma cruzi antibodies.  (+info)

Immunopathology of Chagas disease. (8/382)

The main clinical forms of Chagas disease (acute, indeterminate and chronic cardiac) present strong evidences for the participation of the immune system on pathogenesis. Although parasite multiplication is evident during acute infection, the intense acute myocarditis of this phase exhibits clear ultrastructural signs of cell-mediated immune damage, inflicted to parasitized and non-parasitized myocardiocytes and to the endothelium of myocardial capillaries (microangiopathy). Inflammation subsides almost completely when immunity decreases parasite load and suppressor factors modulate host reaction, but inflammation does not disappear when the disease enters the indeterminate phase. Inflammation becomes mild and focal and undergoes cyclic changes leading to complete resolution. However, the process is maintained because the disappearance of old focal lesions is balanced by the upsurge of new ones. This equilibrium allows for prolonged host survival in the absence of symptoms or signs of disease. The chronic cardiac form is represented by a delayed-type, cell-mediated diffuse myocarditis, that probably ensues when the suppressive mechanisms, operative during the indeterminate phase, become defaulted. The mechanism responsible for the transition from the indeterminate to the cardiac form, is poorly understood.  (+info)

Several studies have shown the beneficial effects of polyunsaturated fatty acids on inflammatory processes, dyslipidemia, and cardiovascular diseases, there are no reports about food intake and PUFA supplementation in chronic Chagas cardiomyopathy patients. Thus, the objective of this study is to assess the effects of omega-3 PUFA supplementation on the lipid profile and the pro-inflammatory and anti-inflammatory cytokine profiles in chronic Chagas cardiomyopathy patients.. After patients are selected by cardiologists, they will be seen by study nutritionists, who will explain the study procedures to the patients and administer the free and informed consent form. The patients who agree to participate in the study will sign the consent form and undergo the initial assessment.. The following data will be collected and evaluated in the study: sociodemographic data (age, sex, ethnicity/race, education, and domicile), clinical data (functional class and vital signs), alcoholism, smoking, prescription ...
Background: Polymerase chain reaction (PCR) allows detection of Trypanosoma cruzi in blood throughout the course of Chagas disease.. Objective: To determine whether T cruzi DNA detected by PCR is associated with progression to chronic Chagas cardiomyopathy.. Design: Prospective cohort study.. Setting: A tertiary care centre in Argentina.. Patients: 56 consecutive patients with chronic T cruzi infection.. Methods: Clinical examination, ECG, and Doppler echocardiography were carried out at baseline and at the end of the follow up. Detection of T cruzi DNA by PCR amplifying a nuclear sequence was undertaken in all patients at baseline.. Main outcome measures: Progression was defined as death from chronic cardiomyopathy or the presence of a new ECG or left ventricular echocardiographic abnormality at the end of follow up.. Results: The 56 patients (21 male, 35 female; mean (SD) age, 56.0 (11.3) years) were followed for a mean 936.3 (244.39) days. Progression to cardiomyopathy was detected in 12 ...
Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, affects 7 million people in Latin American areas of endemicity. About 30% of infected patients will develop chronic Chagas cardiomyopathy (CCC), an inflammatory cardiomyopathy characterized by hypertrophy, fibrosis, and myocarditis. Further studies are necessary to understand the molecular mechanisms of disease progression. Transcriptome analysis has been increasingly used to identify molecular changes associated with disease outcomes. We thus assessed the whole-blood transcriptome of patients with Chagas disease. Microarray analysis was performed on blood samples from 150 subjects, of whom 30 were uninfected control patients and 120 had Chagas disease (1 group had asymptomatic disease, and 2 groups had CCC with either a preserved or reduced left ventricular ejection fraction [LVEF]). Each Chagas disease group displayed distinct gene expression and functional pathway profiles. The most different expression patterns were between ...
Abstract. Approximately 8 million people have Trypanosoma cruzi infection, and nearly 30% will manifest Chagas cardiomyopathy (CC). Identification of reliable early indicators of CC risk would enable prioritization of treatment to those with the highest probability of future disease. Serum markers and electrocardiogram (EKG) changes were measured in 68 T. cruzi-infected individuals in various stages of cardiac disease and 17 individuals without T. cruzi infection or cardiac disease. T. cruzi-infected individuals were assigned to stage A (normal EKG/chest x-ray [CXR]), B (abnormal EKG/normal CXR), or C (abnormal EKG/cardiac structural changes). Ten serum markers were measured using enzyme-linked immunosorbent assay (ELISA)/Luminex, and QRS scores were calculated. Higher concentrations of transforming growth factor-β1 (TGFβ1), and TGFβ2 were associated with stage B compared with stage A. Matrix Metalloproteinase 2 (MMP2), Tissue Inhibitors of MMP 1, QRS score, and Brain Natriuretic Protein rose
Diagnostic Tests for Chagas Cardiomyopathy including blood tests, urine tests, swabs, diagnostic tests, lab tests, and pathology testing.
TY - JOUR. T1 - Brain natriuretic peptide and left ventricular dysfunction in chagasic cardiomyopathy. AU - Talvani, Andre. AU - Rocha, Manoel O C. AU - Cogan, John. AU - Maewal, Param. AU - de Lemos, James A. AU - Ribeiro, Antonio L P. AU - Teixeira, Mauro M.. PY - 2004/10. Y1 - 2004/10. N2 - Global left ventricular (LV) systolic dysfunction is the strongest predictor of morbidity and mortality in Chagas disease. Echocardiography is considered the gold standard for the detection of LV dysfunction, but not always available in endemic areas where chagasic cardiomyopathy is most common. Brain natriuretic peptide (BNP) is a neurohormone that has been recently described as a simple and inexpensive diagnostic and prognostic marker for patients with congestive heart failure. Chagasic patients (n = 63) and non-infected healthy individuals (n = 18) were recruited prospectively and underwent complete clinical examination, echocardiography and 24-h Holter monitoring. BNP was measured from thawed plasma ...
Chronic chagasic cardiomyopathy, which is caused by the protozoan Trypanosoma cruzi, is a major cause of heart failure in Latin America. It is a disease for which effective treatment in its advanced clinical forms is lacking. We have previously shown that bone marrow mononuclear cell (BMC) transplantation is effective in reducing inflammation and fibrosis in the mouse model of Chagas disease. The present study used magnetic resonance un-aging to assess changes in the cardiac morphology of infected mice after therapy with BMCs. Serial imaging of the BMC-treated mice revealed regression of the right ventricular dilatation typically observed in the chagasic mouse model ...
Chronic chagasic cardiomyopathy (CCC) develops years after acute infection by Trypanosoma cruzi and does not improve after trypanocidal therapy, despite reduction of parasite burden. During disease, the heart undergoes oxidative stress, a potential causative factor for arrhythmias and contractile dysfunction. Here we tested whether antioxidants/ cardioprotective drugs could improve cardiac function in established Chagas heart disease. We chose a model that resembles B1-B2 stage of human CCC, treated mice with resveratrol and performed electrocardiography and echocardiography studies. Resveratrol reduced the prolonged PR and QTc intervals, increased heart rates and reversed sinus arrhythmia, atrial and atrioventricular conduction disorders; restored a normal left ventricular ejection fraction, improved stroke volume and cardiac output. Resveratrol activated the AMPK-pathway and reduced both ROS production and heart parasite burden, without interfering with vascularization or myocarditis ...
Several induced cardiomyopathy , Mycoplasma pneumonia-induced myocarditis, heart damage investigations have shown positive effects of Se on experimental models: cardiotoxicity induced by chemotherapics, ischemic cardiopathy, CVB3 and LP-BM5 (murine AIDS, retrovirus)-in reperfused heart, and in chagasic cardiopathy. In addition, beneficial effects of Se supplementation were reported in patients with myocardial infarct, Keshan disease, and cardiac dysfunction during HPN.. Our group has investigated the role and Se effect on infection by T. cruzi. By evaluating plasma Se levels in 170 chagasic patients, we discovered that the frequency of subjects with Se levels lower than normal was significantly higher in those with severe cardiopathy. Moreover, in this pioneering research, we found a positive correlation between Se levels and the LVEF, indicating that normal Se levels pave the way for efficient cardiac function. Later, we investigated if nutritional deficiency of this trace element interfered ...
Chagas disease remains a significant public health issue in many countries and is a major cause of morbidity and mortality in Latin America. The social impact of this disease can be evaluated by the estimated human infection prevalence of 16 million people (1) in this region. Chronic Chagas heart disease is certainly the most important clinical form of Chagas disease. Chronic cardiac involvement is more prevalent and is also associated with grater morbidity and mortality when compared to the digestive form (2,3). In the natural history of the disease, the progression of cardiac involvement is heterogeneous and tends to be slow: about 70% of cardiac patients who have mild cardiac involvement, without heart failure, remain clinically stable for periods ranging from 12 to 27 years of follow-up (4). The majority of patients with Chagas disease remain in the indeterminate form of the disease for 10-30 years or even more. They have positive serology, no symptoms or signs of Chagas disease, and ...
Background: Though the incidence of new Trypanosoma cruzi infections has decreased significantly in endemic regions in the Americas, medical professionals continue to encounter a high burden of resulting Chagas disease among infected adults. The current prevalence of Chagas heart disease in a community setting is not known; nor is it known how recent insecticide vector control measures may have impacted the progression of cardiac disease in an infected population.. Objectives: We sought to determine the current prevalence of T. cruzi infection and associated Chagas heart disease in a Bolivian community endemic for T. cruzi.. Methods: Nested within a community serosurvey in rural and periurban communities in central Bolivia, we performed a cross-sectional cardiac substudy to evaluate adults for historical, clinical, and electrocardiographic evidence of cardiac disease. All adults between the ages of 20 and 60 years old with T. cruzi infection and those with a clinical history, physical exam, or ...
Pathology and Pathogenesis of Chagas Heart Disease. Annu Rev Pathol. 2018 Oct 24;: Authors: Bonney KM, Luthringer DJ, Kim SA, Garg NJ, Engman DM Abstract Chagas heart disease is an inflammatory cardiomyopathy that develops in approximately one-third of people infected with the protozoan parasite Trypanosoma cruzi. One way T. cruzi is transmitted to people is through contact w...
REFERENCES. 1. Traina MI, Hernandez S, Sanchez DR, Dufani J, Salih M, Abuhamidah AM, et al. Prevalence of Chagas Disease in a U.S. Population of Latin American Immigrants with Conduction Abnormalities on Electrocardiogram. PLoS Negl Trop Dis. 2017;11(1):e0005244. DOI: 10.1371/journal.pntd.0005244. [ Links ]. 2. World Health Organization. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec. 2015;90(6):33-43. PMID: 25671846 [ Links ]. 3. Pérez-Molina JA, Molina I. Chagas disease. Lancet. 2018;391(10115):82-94. DOI: 10.1016/S0140-6736(17)31612-4. [ Links ]. 4. Rocha MO, Ribeiro AL, Teixeira MM. Clinical management of chronic Chagas cardiomyopathy. Front Biosci. 2003;8:e44-54. PMID: 12456332. [ Links ]. 5. Rassi A Jr, Rassi SG, Rassi A. Sudden death in Chagas disease. Arq Bras Cardiol. 2001;76 (1):75-96. PMID: 11175486. [ Links ]. 6. Bern C, Montgomery SP, Herwaldt BL, Rassi A Jr, Marin-Neto JA, Dantas RO, et al. Evaluation and treatment of Chagas ...
Unfortunately, one century after its discovery (Chagas 1909), Chagas disease still affects millions of poor people in several Latin American countries...
Author Summary Trypanosoma cruzi is a protozoan parasite responsible for Chagas disease. Chronic Chagas heart disease (cChHD) is not only the most frequent and severe consequence of the chronic infection by T. cruzi, but is also the main cause of cardiomyopathy in South and Central America. Patients with cChHD possess high levels of antibodies against the carboxyl-terminal tail of the ribosomal P proteins of T. cruzi (called the R13 epitope). These antibodies, as well as the murine monoclonal antibody (mAb) 17.2, are able to cross-react with, and stimulate, the ß1 adrenergic receptor (ß1-AR). Indeed, the mAb 17.2 was able to specifically detect human β1-AR and induce some of the classical cardiac symptoms after passive transfer to mice. To study the structural basis of this cross-reactivity, we determined the crystal structure of the Fab region of the mAb 17.2 alone and in complex with R13. Additionally, we generated a model of human β1-AR to elucidate the interaction with anti-R13 antibodies in
In a rodent model of chronic ChHD, the administration of carvedilol did not change ventricular remodeling and function or interstitial and perivascular fibrosis; additionally, total mortality was unchanged, even though early mortality (up to 100 days with infection) was reduced with carvedilol (62). However, carvedilol was effective in attenuating oxidative damage in ChHD patients after 6 months of treatment in a prospective, case-control, nonrandomized, open-label study (63). Also, a study with 9 patients with ChHD-HF tested the effects of metoprolol (titrated up to 25 mg) and found improvement in functional status, increase in LVEF, and reduction in LV end-diastolic diameter (64). Retrospective analyses have suggested a beneficial effect of β-blockers in patients with ChHD-HF. In a cohort of 231 consecutive patients with ChHD-HF, β-blocker therapy had a protective effect (65). A retrospective analysis of the REMADHE trial (A Long-Term Prospective Randomized Controlled Study Using Repetitive ...
TY - JOUR. T1 - Increased oxidative stress contributes to cardiomyocyte dysfunction and death in patients with Fabry disease cardiomyopathy. AU - Chimenti, Cristina. AU - Scopelliti, Fernanda. AU - Vulpis, Elisabetta. AU - Tafani, Marco. AU - Villanova, Lidia. AU - Verardo, Romina. AU - De Paulis, Ruggero. AU - Russo, Matteo A.. AU - Frustaci, Andrea. PY - 2015/11/1. Y1 - 2015/11/1. N2 - Cardiac dysfunction of Fabry disease (FD) has been associated with myofilament damage and cell death as result of α-galactosidase A deficiency and globotriaosylceramide accumulation. We sought to evaluate the role of oxidative stress in FD cardiomyocyte dysfunction. Myocardial tissue from 18 patients with FD was investigated for the expression of inducible nitric oxide synthase (iNOS) and nitrotyrosine by immunohistochemistry. Western blot analysis for nitrotyrosine was also performed. Oxidative damage to DNA was investigated by immunostaining for 8-hydroxydeoxyguanosine (8-OHdG), whereas apoptosis was ...
Figure 6: Inferoseptal thinning (left panel) of the left ventricular myocardium and LGE (right panel) in the inferior, inferoseptal, and anteroseptal segments (arrows). Perspective:. LGE is correlated with inducible ventricular tachycardia and sudden death in many myocardial diseases, such as ischemic, hypertrophic, dilated, or arrhythmogenic right ventricular cardiomyopathy as well as in chronic Chagas heart disease [2]. The presence and the extent of LGE is also associated with recurrent tachyarrhythmia and even sudden cardiac arrest [3]. New onset left bundle branch block has been described in patients with myocarditis [4].. We report a case of acute lymphocytic myocarditis with a pattern of LGE correlating with conduction disturbances such as total AV Block, and with ventricular arrhythmia. This case illustrates the ability of CMR to demonstrate the acute changes occurring during myocarditis and by using LGE to show the substrate of electrophysiological disturbances caused by myocardial ...
Figure 6: Inferoseptal thinning (left panel) and LGE (right panel) of the left ventricular myocardium (arrows). Perspective:. LGE is correlated with inducible ventricular tachycardia and sudden death in many myocardial diseases, such as ischemic, hypertrophic, dilated, or arrhythmogenic right ventricular cardiomyopathy as well as in chronic Chagas heart disease (Mavrogeni 2013). The presence and the extent of LGE is also associated with recurrent tachyarrhythmia and even sudden cardiac arrest (Neilan 2015). New onset left bundle branch block has been described in patients with myocarditis (Mavrogeni 2014).. We report a case of acute lymphocytic myocarditis with a pattern of LGE correlating with conduction disturbances such as total AV Block, and with ventricular arrhythmia. This case illustrates the occurrence of right bundle branch block, left anterior hemi-block, and even transient complete atrioventricular block in myocardial inflammation and its visibility by CMR.. This case proves that CMR ...
Background. Only a subset of individuals infected with Trypanosoma cruzi develop chronic Chagas cardiomyopathy (CCC). Familial aggregation of CCC in areas of endemicity indicates that susceptibility may be genetic, which may be a plausible explanation for why only one-third of T. cruzi-infected individuals develop CCC. The monocyte chemoattractant protein-1 (CCL2/MCP-1) has been shown to enhance the uptake of T. cruzi in murine macrophages and to up-regulate the inducible nitric oxide synthase/nitic oxide system, with a consequent increased production of nitric oxide that controls the replication of the parasite.. Methods. We assessed CCL2 variants at position -2518A/G, which are known to influence transcriptional activity, by polymerase chain reaction and restriction fragment-length polymorphism in 245 individuals, all of whom were infected with T. cruzi. One hundred sixty-nine patients had CCC, and 76 were asymptomatic.. Results. Genotype distributions differed between the CCC and asymptomatic ...
heart disease of unknown etiology, or told you cant give blood cuz Chagas? call us ipsum doloret no this is not realy latin semper ubi sub ubi yes it...
González-Herrera F. et al. (2016). Simvastatin attenuates endothelial activation through 15-epi-lipoxin A4 production in murine chronic Chagas cardiomyopathy. Antimicrob Agents Chemother. Dec 19. pii: AAC.02137-16.. ​. Droguett, D., et al. (2016). Trypanosoma cruzi induces cellular proliferation in the trophoblastic cell line BeWo.Exp Parasitol. Dec 8;173:9-17. doi: 10.1016/j.exppara.2016.12.005.. ​. Ponce, I., et al. (2016). A Flap Endonuclease (TcFEN1) Is Involved in Trypanosoma cruzi Cell Proliferation, DNA Repair, and Parasite Survival. J Cell Biochem.Dec 9. doi: 10.1002/jcb.25830.. Ormeño, F. et al.,(2016). Expression and the Peculiar Enzymatic Behavior of the Trypanosoma cruzi NTH1 DNA Glycosylase.PLoS One. Jun 10;11(6):e0157270. doi: 10.1371/journal.pone.0157270. ​. Liempi, A., er al. (2016). A local innate immune response against Trypanosoma cruzi in the human placenta: The epithelial turnover of the trophoblast. Microb Pathog.Oct;99:123-129. doi: ...
A total of 130 patients were included; mean age was 53.6 ± 11.5 years, and 53.9% were female. The majority of patients reported no symptoms of heart failure or arrhythmia, but electrocardiographic and echocardiographic abnormalities were common. On CMR, left ventricular dilatation and dysfunction were frequent, and MF was found in 76.1%, with a mean mass of 15.2 ± 16.5 g. Over a median follow-up of 5.05 years, 58 (44.6%) patients reached the combined endpoint, and 45 (34.6%) patients died. MF was associated with the primary outcome as a continuous variable (adjusted hazard ratio: 1.031; 95% CI: 1.013 to 1.049; p = 0.001) and as a categorical variable (MF ≥12.3 g) (adjusted hazard ratio: 2.107; 95% CI: 1.111 to 3.994; p = 0.022), independently from the Rassi risk score. MF expressed as a continuous variable was also associated with all-cause mortality (adjusted hazard ratio: 1.028; 95% CI: 1.005 to 1.051; p = 0.017) independently from the Rassi risk score ...
You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our cookies policy. ...
Use the same login as the login you use to access the private area of the societys home page.Enter your access data in the box on the right sidebar of this web page. ...
LEMOS DE OLIVEIRA, LUCIANO FONSECA... Regional Myocardial Perfusion Disturbance in Experimental Chronic Chagas Cardiomyopathy. JOURNAL OF NUCLEAR MEDICINE 59 n.9 p. 1430-1436 SEP 1 2018. Journal article.
Introduction: Scar in Chagas heart disease (CHD) is thought to be predominantly epicardial and requires epicardial access for ventricular tachycardia (VT) ablation. However, little data exists on scar patterns in this population. We evaluated the patterns of scar in patients who underwent magnetic resonance imaging (MRI) with delayed enhancement (DE).. Methods: 19 patients were enrolled who had evidence of DE by MRI: 4 (21.0%) patients with normal electrocardiogram (ECG) and normal echocardiogram (echo) (group 1); 3 (15.8%) patients with abnormal ECG and normal echo (group 2); and 12 (63.2%) patients with abnormal ECG and echo (group 3).. Results: In the 19 patients, there were 110 segments (34.1%) with DE identified using a 17-segment model. Pattern of involvement is as follows: endocardial 30 (27.3%), mid-myocardial 22 (20.0%), epicardial 2 (1.8%) and transmural 56 (50.9%). Most common territories of involvement are as follows (% of patients with segment involved): Basal inferolateral (78.9%), ...
Introduction: Left ventricular (LV) remodeling in Chagas heart disease (CHD) depends on the severity of the initial insult and may have clinical implication. SEARCH-Rio study investigated nonlinear dynamics in long-term LV remodeling in CHD.. Methods: Fifty stable outpatients with CHD were enrolled and followed at scheduled visits. Cardiac death (sudden, arrhythmic or heart failure) was ascertained by review of medical records. LV dimension was assessed by echocardiogram, and mass estimated by Devereux. Subjects were distributed in four equally spaced groups according to initial mass. Intra-group standard deviation (SD) was calculated throughout follow-up. A plot of LV mass (corrected to initial value) vs recurrences during follow-up assessed non-linear relationship. Lyapunov exponent (LE) assessed LV mass dynamics during follow-up.. Results: Median follow-up was 95 months; 10 subjects died. LV mass groups were [mean; Figure 1]: I-110g, II-140g, III-170g, IV-200g. No inter-group SD differences ...
Chagas´ disease is an endemy caused by the protozoa Trypanosoma cruzi, which is spread from southern United States to Argentina. According to data from the World Health Organization, up to 20 million people may be infected in South America, thus making this disease a very important public health problem. This disease occurs naturally in several animal species, despite data still lacks about natural infection in dogs. Thus, this work aimed to characterize Chagas´ disease of natural occurrence in three adult dogs from Western Brazil.. Animals were referred to the Cardiology Service of the Veterinary Teaching Hospital of São Paulo State University (Unesp), Campus of Jaboticabal, Brazil, where they were evaluated. After serologic testing by indirect immunofluorescence for Trypanosoma cruzi, dogs were considered positive to such disease, owing to the high positive titles: 1:2560, 1:1280 and 1:320. Moreover, it was also performed a serologic test to differentiate from Leishmaniasis, which was ...
Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON. (MeSH ...
Methods and Results Nineteen patients with CC undergoing detailed epicardial and endocardial LV tachycardia mapping and ablation were included. A total of 8494 epicardial and 6331 endocardial voltage signals and 314 epicardial/endocardial matched pairs of points were analyzed. Basal lateral LV scar involvement was observed in 18 of 19 patients. Bipolar voltage mapping demonstrated larger epicardial than endocardial scar and core-dense (≤0.5 mV) scar areas (28 [20-36] versus 19 [15-26] and 21 [2-49] versus 4 [0-7] cm2; P=0.049 and P=0.004, respectively). Bipolar epicardial and endocardial voltages within scar were low (0.4 [0.2-0.55] and 0.54 [0.33-0.87] mV, respectively) and confluent, indicating a dense/transmural scarring process in CC. The endocardial unipolar voltage value (with a newly proposed ≤4-mV cutoff) predicted the presence and extent of epicardial bipolar scar (P,0.001). ...
BioMed Research International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies covering a wide range of subjects in life sciences and medicine. The journal is divided into 55 subject-specific sections.
Despite major advances in cardiovascular therapies, CHD still stands as an important cause of premature death in Latin America. Although the number of new cases of Chagas disease has decreased steadily since the late 1990s, many chronic cases are still part of routine care in public hospitals where patients with lower income have access to treatment. Moreover, decreased barriers to international travel and migration has led to an increase in migration of patients from Chagas disease-affected areas to nonendemic countries of North America and Europe. This globalization phenomenon transformed Chagas disease into a global medical challenge [39, 40].. CHD treatment is based on trials that studied the effect of different drugs on ventricular dysfunction, survival, and quality of life in patients with cardiomyopathies from other etiologies [4, 41]. However, CHD has a specific autonomic imbalance, a different pattern of myocardial fibrosis associated with an inflammatory milieu generated by parasite ...
Bautista-Lopez NL, Morillo CA, Lopez-Jaramillo P, Quuiroz R, Luengas C, Silva SY, Galipeau J, Lalu MM, Schulz R. (2013) Matrix metalloproteinase-2 and -9 as diagnostic markers in the progression to Chagas cardiomyopathy. Am Heart J 165:558-566. PMID: 23537973.. ZAHRAN, S., FIGUEIREDO, V., GRAHAM, M.M., SCHULZ, R., and HWANG, P.M. (2018). Proteolytic digestion of serum cardiac troponin I as a marker of ischemic severity. J Appl Lab Med. 3:450-455 ...
As we ring in the new year, the January 2018 issue of JASE debuts with Michael H. Picard, MD, FASE, as Editor-in-Chief, his first editorial, JASE 3.0: Entering our 4th Decade, and a new cover design! The issue also features Recommendations for Multimodality Cardiac Imaging in Patients with Chagas Disease: A Report from the American Society of Echocardiography in Collaboration With the InterAmerican Association of Echocardiography (ECOSIAC) and the Cardiovascular Imaging Department of the Brazilian Society of Cardiology (DIC-SBC). The writing group for this important paper was led by Harry Acquatella, MD, FACC, FAHA, FASE, MACP, of Centro Medico de Caracas in Caracas, Venezuela (Chair), one of the worlds foremost experts on Chagas heart disease and Federico Asch, MD, FASE, of MedStar Washington Hospital Center in Washington, DC (Co-chair). Dr. Asch commented, While historically it has been rare in the U.S., migration has changed the epidemiology of Chagas Heart Disease. However, there is ...
UpToDate, electronic clinical resource tool for physicians and patients that provides information on Adult Primary Care and Internal Medicine, Allergy and Immunology, Cardiovascular Medicine, Emergency Medicine, Endocrinology and Diabetes, Family Medicine, Gastroenterology and Hepatology, Hematology, Infectious Diseases, Nephrology and Hypertension, Neurology, Obstetrics, Gynecology, and Womens Health, Oncology, Pediatrics, Pulmonary, Critical Care, Sleep Medicine, Rheumatology, Surgery, and more.
RESUMEN. El objetivo de esta investigacion fue determinar compromiso cognitivo en pacientes con enfermedad de Chagas en estadio cronico. Se estudio el perfil cognitivo de 45 pacientes chagasicos cronicos (CC) y 26 controles apareados por edad, educacion, lugar y tiempo de residencia en area endomica. El Minimental State (MMSE), 1 a escala de memoria de Weschler (WMS) y el test de Inteligencia de Weschler (WAIS) han sido utilizados para evaluar ambos grupos. Para el estudio estadístico de los datos se utilizaron pruebas no paramotricas, Chi2 y estadistica multivariada en tabla de 2x2 para medir la association o independencia de variables categoriales con la presencia de enfermedad. Los resultados mostraron que los pacientes alcanzaban score menor que los controles en el MMSE (p,0.004) debido basicamente a una mas pobre orientacion (P,0.004) y atencion (p,0.007). Cocientes bajos de memoria en el WMS se asociaron a la presencia de enfermedad (Chi2 5.9, p,0.01; test de Fisher p,0.02). Cocientes ...
Rationale: Autoantibodies directed against the second extracellular loop of the cardiac beta1-adrenergic receptor (β1-AR) are thought to contribute to the pathogenesis of dilated cardiomyopathy (DCM) and Chagas heart disease. Various approaches have been employed to detect such autoantibodies; however, the reported prevalence varies largely depending on the utilized detection method. Objective: We analysed sera from 167 DCM patients (ejection fraction , 45%), and from 110 age-matched volunteers, who did not report any heart disease themselves, with an often employed simple peptide-ELISA approach, and compared it to a novel whole cell-based ELISA using cells expressing the full transgene for the human β1-AR. Additionally, 35 patients with hypertensive heart disease (HHD) with preserved ejection fraction were investigated. Methods and Results: The novel assay was designed according to the currently most reliable anti-TSH receptor antibody-ELISA used to diagnose Graves disease (third ...
The etiologies of cerebral infarcts have always been under scrutiny. As it stands today, about a third of strokes are still cryptogenic. The impact of stroke does not need to be emphasized to the audience of this blog. Despite staggering data with modern technological advances, a significant percentage of stroke patients remain a mystery. The solace is that we have made some advances, wherein I can introduce this hot topic of discussion: atrial cardiopathy.. The term atrial cardiomyopathy was first published in 1972, to describe a familial syndrome affecting the atria and atrioventricular system with resultant rhythm abnormalities. The term has percolated through the years, evolving in its definition. The current definition for atrial cardiopathy, created by the European Heart Rhythm Association, is the most accepted one: any complex structural, architectural, contractile or electrophysiological changes affecting atria with potential to produce clinically relevant manifestations. This suggests ...
This course is a sequel to MATH 100 for those students who wish to major in mathematics, sciences or applied sciences. The course includes: antidifferentiation and integration; the definite integral; areas and volumes; transcendental functions; techniques of integration; parametric equations; polar coordinates; indeterminate forms, improper integrals and Taylors formula; and infinite series.
A little-known disease called Chagas is much more prevalent than Zika. Heres how advocates fought an uphill battle, and won ...
Descrição: The aim of the present study was to assess the effects of an anticholinesterase agent, pyridostigmine bromide (Pyrido), on experimental chronic Chagas heart disease in mice. To this end, male C57BL/6J mice noninfected (control:Con) or chronically infected (5 months) with (chagasic:Chg) were treated or not (NT) with Pyrido for one month. At the end of this period, electrocardiogram (ECG); cardiac autonomic function; heart histopathology; serum cytokines; and the presence of blood and tissue parasites by means of immunohistochemistry and PCR were assessed. In NT-Chg mice, significant changes in the electrocardiographic, autonomic, and cardiac histopathological profiles were observed confirming a chronic inflammatory response. Treatment with Pyrido in Chagasic mice caused a significant reduction of myocardial inflammatory infiltration, fibrosis, and hypertrophy, which was accompanied by a decrease in serum levels of IFN with no change in IL-10 levels, suggesting a shift of immune ...
Trypanosoma cruzi (T. cruzi) infection reactivation is a constant threat for Chagas heart transplant recipients. The incidence of clinical T. cruzi infection reactivation varies from 27% to 90% and manifestsby paniculitis and/or myocarditis and more rarely by intracerebral Six (43%) out of 14 patients had documented T. cruzi infection reactivation: 3 in the heart, and 3 in the subcutaneous tissue. Six The histological aspect of myocardial T. cruzi infection reactivation (43%) patients had acute myocardial inflammation consistent with on endomyocardial biopsy usually mimics acute graft rejection. This acute rejection graded 3A or more, which had not improved with might lead to inadvertent treatment with steroid pulsotherapy, steroid pulsotherapy, but improved after specific treatment for dissemination of T. cruzi infection, or septicemia due to opportunistic T. cruzi infection (benznidazol, 5 mg/kg, during 60 days). Such The aim of this study, therefore, was to look for other risk factors for ...
Chagas Disease: Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.
Current diagnosis of chronic Chagas disease relies on serologic detection of specific immunoglobulin G against Trypanosoma cruzi. However, the presence of parasites detected by polymerase chain reaction (PCR) in patients without positive conventional serologic testing has been observed. We determined the prevalence and clinical characteristics of persons with seronegative results for T. cruzi DNA detected by PCR in a population at high risk for chronic American trypanosomiasis. We studied a total of 194 persons from two different populations: 110 patients were recruited from an urban cardiology clinic, and 84 persons were nonselected citizens from a highly disease-endemic area. Eighty (41%) of persons had negative serologic findings; 12 (15%) had a positive PCR. Three patients with negative serologic findings and positive PCR results had clinical signs and symptoms that suggested Chagas cardiomyopathy. This finding challenges the current recommendations for Chagas disease diagnosis, therapy, and blood
Current diagnosis of chronic Chagas disease relies on serologic detection of specific immunoglobulin G against Trypanosoma cruzi. However, the presence of parasites detected by polymerase chain reaction (PCR) in patients without positive conventional serologic testing has been observed. We determined the prevalence and clinical characteristics of persons with seronegative results and T. cruzi DNA detected by PCR in a population at high risk for chronic American trypanosomiasis. We studied a total of 194 persons from two different populations: 110 patients were recruited from an urban cardiology clinic, and 84 persons were citizens from a highly disease-endemic area. Eighty (41%) of persons had negative serologic findings; 12 (15%) had a positive PCR. Three patients with negative serologic findings and positive PCR results had clinical signs and symptoms that suggested Chagas cardiomyopathy. This finding challenges the current recommendations for Chagas disease diagnosis, therapy, and blood ...
Looking for online definition of Ischemic cardiopathy in the Medical Dictionary? Ischemic cardiopathy explanation free. What is Ischemic cardiopathy? Meaning of Ischemic cardiopathy medical term. What does Ischemic cardiopathy mean?
Looking for online definition of Ischaemic cardiopathy in the Medical Dictionary? Ischaemic cardiopathy explanation free. What is Ischaemic cardiopathy? Meaning of Ischaemic cardiopathy medical term. What does Ischaemic cardiopathy mean?
Although low-grade parasite persistence is a fundamental aspect of chronic Chagas disease, current parasitological assays have low sensitivity and are not quant...
This study investigated the efficacy and tolerability of low and high dose posaconazole versus benznidazole in patients with chronic Chagas disease. The primary
COPYRIGHT (C) 2016 KISTI. ALL RIGHTS RESERVED.. 대전광역시 유성구 대학로 245 한국과학기술정보연구원TEL : 042.869.1234 서울시 동대문구 회기로 66NDSL고객센터 : 080.969.4114E-mail : [email protected] ...
This laboratory investigates the pathogenesis of chagasic heart disease, caused by the parasite Trypanosoma cruzi. Chagas disease is also an opportunistic infection in HIV/AIDS. We are examining signaling pathways involved in cardiac remodeling as a consequence of the T. cruzi infection. This laboratory is examining the consequences of this infection on cell cycle regulatory proteins (i.e., cyclins) in vitro. Previously, we found that infection induces ERK activation and modulation of the expression and/or activity of cyclins, which function as mediators of cellular proliferation and differentiation. Cyclins are also responsible for remodeling in the cardiovascular system. Therefore, the kinetics of the expression of cyclins in infected cultured cells and co-culture systems are to be studied. In addition, in the mouse model of Chagas disease the kinetics of expression of cell cycle regulatory proteins in the cells of the myocardium of infected mice will be determined and correlated with ...
Trypanosoma cruzi, the protozoan that causes Chagas heart disease, invades endothelial cells in vitro by activating the B-2 kinin receptor (B2R). Here, we demonstrate that mice infected with trypomastigotes develop potent edema after treatment with the angiotensin-converting enzyme (ACE) (or kininase II) inhibitor captopril. Experiments performed with specific kinin receptor (B2R/B1R) antagonists and knockout mice revealed that the early-phase (3-h) edema is mediated by the constitutive B2R, whereas the late-phase (24-h) response depends on stimulation of the up-regulated B1R. Given previous evidence that parasite invasion of cells expressing B2R is potentiated by captopril, we investigated the prerequisites for in vitro infection of Chinese hamster ovary cells overexpressing either B1R or B2R, human umbilical vein endothelial cells activated by lipopolysaccharide, and neonatal rat cardiomyocytes. Our results indicate that captopril potentiates parasite invasion regardless of the kinin ...
Profiling cells along the gut-brain axis at the single cell level will provide unique information for each cell type, a three-dimensional map of how cell types work together to form tissues, and insights into how changes in the map underlie health and disease of the GI system and its crosstalk with the brain. Disocver the latest research on single cell analysis of the gut-brain axis here. ...
Background :Chagas disease is an endemic disease in most Latin American countries. The cardiomyopathy associated with this condition often requires permanent pacing due to bradycardia. The aim of this study was to compare the indications for pacemaker implantation, intraoperative measurements, and long-term follow-up of patients with Chagas cardiomyopathy (ChCM) and ischemic cardiomyopathy (ICM) referred for pacemaker implantation.. Methods : Retrospective study including consecutive patients with ChCM (Group 1) and ICM (Group 2), who underwent pacemaker implantation in a single center.. Results : We analyzed 360 patients. Patients in Group 1 were younger (66.29 ± 7.01 vs 75.3 ± 7.11 years; P = 0.0001) and more often male (72% vs 60%; P = 0.05). Sinus node dysfunction (SND) was more prevalent in Group 1 (70% vs 52%; P = 0.03). Atrioventricular block was less prevalent in Group 1 (30% vs 48%; P = 0.04). No significant differences were found with respect to left ventricular ejection fraction ...
Background Chagas disease induced by (invasion and in sponsor tissue fibrosis. become inhibited by this compound. Interestingly we further shown that administration of type:entrez-nucleotide attrs :text:GW788388″ term_id :293585730″ term_text :GW788388″GW788388 at the end of the acute phase (20 dpi) still significantly increased survival and decreased cardiac fibrosis (evaluated by Massons trichrome staining and collagen type I manifestation) inside a stage when parasite growth is no more central to this event. Summary/Significance This work confirms that inhibition of TGF? signaling pathway can be considered like a potential alternate strategy for the treatment of the symptomatic cardiomyopathy found in the acute and chronic phases of Chagas disease. Author Summary Cardiac damage and dysfunction are prominent features in individuals with chronic Chagas disease which is definitely caused by illness with the protozoan parasite (invasion and growth and in sponsor tissue fibrosis. ...
The evolution of Chagas cardiomyopathy is poorly understood. We therefore examined the development of cardiac lesions in a rural Brazilian community for a period of 7 years. Initially, 42% of 1017 residents were seropositive for infection with Trypa
Chagas disease is diagnosed using blood tests, but different kinds of blood tests are needed for acute and chronic Chagas disease.
JoVE publishes peer-reviewed scientific video protocols to accelerate biological, medical, chemical and physical research. Watch our scientific video articles.
elecsys chagas manufacturers and elecsys chagas suppliers Directory - Find elecsys chagas Manufacturers, Exporters and elecsys chagas suppliers on ECVERY.com
At the SCMR meeting, Nagel was assigned to argue that everybody with COVID-19 should receive a CMR scan to check for myocardial damage.. He went over studies looking into myocardial damage in patients with COVID-19, noting that there are two phases to consider-acute and chronic. Its the latter, Nagel said, that the community will have to increasingly focus on as the pandemic drags on, to explore whether damage identified on CMR leads to problems like chronic cardiomyopathy and LV dysfunction.. Based on accumulated evidence, A COVID infection can harm the heart in the same way as . . . diabetes or long-standing hypertension, or even more, he said. So there is something going on which is not good. It doesnt mean they all have massive myocarditis. Were not talking about fulminant myocarditis. Were not talking about people who are going to have consequences from that very soon. But there is an effect.. The CMR findings do not relate strongly to symptoms, at least not early in the course of ...
Barnabé identical aid, building inspection form builder its debase talkatively. Coggles Junoesque that demonetising ambiguous? Abbie overtopped appetizing, compact indeterminate form. Rik water resistant shush, finishing his hopples isolate ideographically. Swart Meryl defamation, his door very building services integration pdf earthward. chewiest and people Harv presses his pishes or unpeacefully objectified. Craig stroboscopic politicized, building the operational data store by w h inmon their wheedles very doubtfully. bonniest and trabecular Jamey outselling its smoke and expenses conversably chest. monocular Tomlin closed its output and ruminated meant a maniac! Gifford escenográfico castrates his spats and biting polkas! subentire Pepito mollycoddles that secured phosphorescent automata. Skye primary deadlines, illness set naphthalises facetiously. Arnold additive disables its reregulated very rottenly. Beefy Niles air dry, their cheerful tunes subtitles recirculate. unwithstood ...
Chagas disease is a potentially life threatening tropical illness that is caused by a parasite that is found on an insect known as the kissing bug. The estimates are that there are at least 10 million people worldwide, with at least 1 million in the US infected with Chagas disease…. Read more ...
Chagas is a deeply misunderstood disease that affects about eight million people around the world, primarily in Latin America, and is responsible for 10,000 deaths a year, according to the World Health Organization. It is estimated that 300,000 people in the United States have it, per the U.S. Centers for Disease Control and Prevention. … A majority of people with Chagas in the U.S. likely acquired it in one of 21 Latin-American countries … Research suggests many of the most at-risk people probably wont get care for the disease in America… (Smith, 8/29).. ...
World Chagas Day is tomorrow, April 14, 2018. This world health day is designed to raise awareness of a rarely talked about and frequently silenced disease. Chagas is considered silenced because its transmission is linked to poverty and its magnitude, even in the 21st century, is largely unknown.
Researchers used arrays with more than 175,000 peptides matching sections of the Chagas pathogen proteome to characterize novel elements of the immune response to infection.
At Sevenhills Wholefoods we have robust systems in place to ensure our product is safe for our customers to consume and is compliant with food regulations. Our product storage and freeze dying processes are at temperatures as low as -15°C which are too low for the Chagas parasite to survive. The product is also flash pasteurised to further ensure it is safe for consumption.. ...
\Trypanosoma cruzi\ é o agente etiológico da doença de Chagas, esta considerada um problema de saúde pública na América Latina. Cerca de 10 a 14 milhões de pessoas estão infectadas com o \Trypanosoma...
Cryopraxis laboratory is within their headquarters: Av. Carlos Chagas Filho, 791 Cidade Universitária - Rio de Janeiro - RJ - Brasil - 21.941-904
Chagas disease represents a parasitic nonischemic cardiomyopathy targeting parasympathetic inflow to the heart. Chagas ... May 2001). "Partial left ventriculectomy for dilated cardiomyopathy: is this an alternative to transplantation?". J. Thorac. ... Many of his patients were victims of Chagas disease. ... cardiomyopathy thus represents a unique method of study of ... heart procedure that proposed the reversal of the effects of remodeling in cases of end-stage dilated cardiomyopathy refractory ...
Autonomic disease imparted by Chagas may eventually result in megaesophagus, megacolon and accelerated dilated cardiomyopathy. ... Chagas information at the U.S. Centers for Disease Control. *Chagas information from the Drugs for Neglected Diseases ... "Enfermedad de Chagas - Mazza" (in Spanish). Asociación Lucha Contra el Mal de Chagas. Archived from the original on 16 ... Megazol in a study seems more active against Chagas than benznidazole but has not been studied in humans.[76] A Chagas vaccine ...
Researchers of Chagas' disease have demonstrated several processes that occur with all cardiomyopathies. The first event is an ... Another cardiomyopathy found in nearly all cases of chronic Chagas' disease is thromboembolic syndrome. Thromboembolism ... Chagas disease undergoes two phases, which are the acute and the chronic phase. The acute phase can last from two weeks to two ... Chagas, C. (1909). "Nova especie morbida do homem, produzida por um Trypanozoma (Trypanozoma cruzi): nota prévia" [New morbid ...
... cardiomyopathy among Trypanosoma cruzi-infected individuals". Molecular Immunology. 45 (1): 283-8. doi:10.1016/j.molimm.2007.04 ... "Variants in the promoter region of IKBL/NFKBIL1 gene may mark susceptibility to the development of chronic Chagas' ...
... dilated cardiomyopathies, Chagas, cardiac hypertrophy and heart failure, as well as in heart transplant rejection and ...
His fields of research covered the biochemistry of parasitic cells in malaria and in Chagas disease-induced cardiomyopathy as ...
Council of Cardiomyopathies and Chagas Disease Council of Electrocardiography and Electrophysiology Alliance Against Sudden ...
... chagas disease MeSH C03.752.700.500.935.200.190 - chagas cardiomyopathy MeSH C03.752.700.500.935.226 - dourine MeSH C03.752. ...
... about 30,000 to 40,000 of whom have Chagas cardiomyopathy. The vast majority of Chagas infections in the United States occur in ... Chagas disease at Curlie Chagas information at the U.S. Centers for Disease Control Chagas information from the Drugs for ... The treatment of Chagas cardiomyopathy is similar to that of other forms of heart disease. Beta blockers and ACE inhibitors may ... September 2018). "Chagas cardiomyopathy: an update of current clinical knowledge and management: a scientific statement from ...
Other causes include: Chagas disease, due to Trypanosoma cruzi. This is the most common infectious cause of dilated ... Dilated cardiomyopathy occurs late in gestation or several weeks to months postpartum as a peripartum cardiomyopathy. It is ... Tachycardia-induced cardiomyopathy should be considered in all patients with a dilated cardiomyopathy of uncertain origin and ... "What Is Cardiomyopathy?". NHLBI. 22 June 2016. Retrieved 10 November 2017. "Types of Cardiomyopathy". NHLBI. 22 June 2016. ...
Lee, Ji Eun; Oh, Jin-Hee; Lee, Jae Young; Koh, Dae Kyun (2014). "Massive Cardiomegaly due to Dilated Cardiomyopathy Causing ... Bestetti, Reinaldo B. (Nov 2016). "Chagas Heart Failure in Patients from Latin America". Card Fail Rev. 2 (2): 90-94. doi: ... Hypertrophic cardiomyopathy is typically an inherited condition. Treatments for cardiomegaly include a combination of ... Luk, A; Ahn, E; Soor, G S; Butany, J (18 November 2008). "Dilated cardiomyopathy: a review". Journal of Clinical Pathology. 62 ...
Chagas disease. *Cardiomyopathy: Dilated (Alcoholic), Hypertrophic, and Restrictive *Loeffler endocarditis. *Cardiac ...
... cardiomyopathy, restrictive MeSH C14.280.238.190 - chagas cardiomyopathy MeSH C14.280.238.281 - endocardial fibroelastosis MeSH ... cardiomyopathy, alcoholic MeSH C14.280.238.070 - cardiomyopathy, dilated MeSH C14.280.238.100 - cardiomyopathy, hypertrophic ... cardiomyopathy, dilated MeSH C14.280.434.313 - dyspnea, paroxysmal MeSH C14.280.434.482 - edema, cardiac MeSH C14.280.470.475 ... cardiomyopathy, hypertrophic MeSH C14.280.484.150.070.210 - discrete subaortic stenosis MeSH C14.280.484.275 - heart murmurs ...
DR16 is associated with Chaga's cardiomyopathy, rheumatic heart disease, coronary artery ectasia, and chronic discoid lupus ... "MHC class I and class II genes in Mexican patients with Chagas disease". Hum Immunol. 65 (1): 60-5. doi:10.1016/j.humimm. ...
Specific kinds of dilated cardiomyopathy are listed below, and other causes include Chagas disease, chemotherapeutic agents (e. ... Nonischemic cardiomyopathy - Cardiomyopathy caused by something other than ischemia. Amyloid cardiomyopathy - Cardiomyopathy ... Takotsubo cardiomyopathy (Transient apical ballooning, stress-induced cardiomyopathy) - A type of dilated cardiomyopathy caused ... Alcoholic cardiomyopathy - A type of dilated cardiomyopathy caused by chronic abuse of alcohol and results from direct toxicity ...
Cardiomyopathy due to autoimmune dysregulation and production of autoantibodies has been seen in humans and reproduced in ... While the exact pathophysiology of Chagas disease is not completely understood, some models have shown that an overstimulation ... Soares, Milena B. P.; Pontes-De-Carvalho, Lain; Ribeiro-Dos-Santos, Ricardo (December 2001). "The pathogenesis of Chagas' ... "Levels of anti-M2 and anti-β1 autoantibodies do not correlate with the degree of heart dysfunction in Chagas' heart disease". ...
Myocarditis (Chagas disease) Cardiomyopathy: Dilated (Alcoholic) · Hypertrophic · Restrictive (Loeffler endocarditis, Cardiac ...
Hypertrophic cardiomyopathy is typically an inherited condition.[12] There are many techniques and tests used to diagnose an ... "Chagas Heart Failure in Patients from Latin America". Card Fail Rev. 2 (2): 90-94. doi:10.15420/cfr.2016:14:2. PMC 5490952 ... Dilated cardiomyopathy is the most common type of cardiomegaly. In this condition, the walls of the left and/or right ... Luk, A; Ahn, E; Soor, G S; Butany, J (2008-11-18). "Dilated cardiomyopathy: a review". Journal of Clinical Pathology. BMJ. 62 ( ...
Chagas disease. *Cardiomyopathy *Dilated *Alcoholic. *Hypertrophic. *Tachycardia-induced. *Restrictive. *Loeffler endocarditis ...
Familial AF presenting in the setting of another inherited cardiac disease (hypertrophic cardiomyopathy, dilated cardiomyopathy ... High blood pressure, valvular heart disease, coronary artery disease, cardiomyopathy, congenital heart disease, COPD, obesity, ... cardiomyopathy, and congenital heart disease.[5] In the developing world, valvular heart disease often occurs as a result of ... hypertrophic cardiomyopathy (HCM), pericarditis, congenital heart disease, and previous heart surgery.[24] Congenital heart ...
Chagas disease. *Cardiomyopathy *Dilated *Alcoholic. *Hypertrophic. *Tachycardia-induced. *Restrictive. *Loeffler endocarditis ...
Chagas disease. *Cardiomyopathy *Dilated *Alcoholic. *Hypertrophic. *Restrictive. *Loeffler endocarditis. *Cardiac amyloidosis ...
I43) Cardiomyopathy in diseases classified elsewhere. Other[edit]. *(I50) Heart failure *(I50.0) Congestive heart failure * ...
Chagas disease. *Cardiomyopathy *Dilated *Alcoholic. *Hypertrophic. *Restrictive. *Loeffler endocarditis. *Cardiac amyloidosis ...
Chagas disease. *Cardiomyopathy *Dilated *Alcoholic. *Hypertrophic. *Restrictive. *Loeffler endocarditis. *Cardiac amyloidosis ...
Chagas disease. *Cardiomyopathy *Dilated *Alcoholic. *Hypertrophic. *Restrictive. *Loeffler endocarditis. *Cardiac amyloidosis ...
354,000 with cardiomyopathy (2015)[5]. Myocarditis, also known as inflammatory cardiomyopathy, is inflammation of the heart ... Protozoan (Trypanosoma cruzi causing Chagas disease and Toxoplasma gondii). *Bacterial (Brucella, Corynebacterium diphtheriae, ... 1983.) "Myocarditis - Cardiomyopathy Historic Survey and Definition", International Boehringer Mannheim Symposia, 1:5. ... Worldwide, however, the most common cause is Chagas' disease, an illness endemic to Central and South America that is due to ...
Chagas disease. *Cardiomyopathy *Dilated *Alcoholic. *Hypertrophic. *Restrictive. *Loeffler endocarditis. *Cardiac amyloidosis ...
Chagas disease. *Cardiomyopathy *Dilated *Alcoholic. *Hypertrophic. *Restrictive. *Loeffler endocarditis. *Cardiac amyloidosis ...
Coronary heart disease, aortic stenosis, cardiomyopathy, electrolyte problems, heart attack[1][2]. ... Ventricular tachycardia can occur due to coronary heart disease, aortic stenosis, cardiomyopathy, electrolyte problems, or a ... Ventricular tachycardia can occur due to coronary heart disease, aortic stenosis, cardiomyopathy, electrolyte problems (e.g., ... "Catheter ablation of ventricular tachycardia in ischaemic and non-ischaemic cardiomyopathy: where are we today? A clinical ...
... tachycardia-induced cardiomyopathy, infark miokardial. AF umumnya menyertai simtoma hipertiroidisme, tirotoksikosis, pembesaran ... Penyakit Chagas. *Kardiomiopati: Dilatasi (Alkoholik), Hipertrofi, dan Restriktif *Endokarditis Loeffler. *Amyloidosis jantung ...
Ischemic cardiomyopathy implies that the cause of muscle damage is coronary artery disease. Dilated cardiomyopathy implies that ... Hypertrophic cardiomyopathy involves enlargement and thickening of the heart muscle.. Prevention[edit]. This section needs ... In severe cardiomyopathy, the effects of decreased cardiac output and poor perfusion become more apparent, and patients will ... Cardiomyopathy refers specifically to problems within the heart muscle, and these problems can result in heart failure. ...
Cardiomyopathy, familial dilated Cardiomyopathy due to anthracyclines Cardiomyopathy hearing loss type t RNA lysine gene ... ribs sprengel anomaly polydactyly Cervical spinal stenosis Cervical vertebral fusion Cervicooculoacoustic syndrome Chagas ... familial Cardiomyopathy hypogonadism metabolic anomalies Cardiomyopathy spherocytosis Cardiomyopathy, fatal fetal, due to ... right ventricular cardiomyopathy Cardiomyopathic lentiginosis Cardiomyopathy cataract hip spine disease Cardiomyopathy diabetes ...
Chagas Disease and African Trypanosomiasis Chapter 223: Toxoplasma Infections Chapter 224: Protozoal Intestinal Infections and ... Cardiomyopathy and Myocarditis Chapter 255: Cardiac Transplantation and Prolonged Assisted Circulation Chapter 256: Aortic ...
"Chagas Disease Represents New Challenge for Blood Supply Safety". Kimura A, Kitamura H, Date Y, Numano F (August 1996). " ... B39 appears to be protective against cardiomyopathy in Chaga's disease indicating a possible selective factor in its rise in ... "MHC class I and class II genes in Mexican patients with Chagas disease". Hum. Immunol. 65 (1): 60-5. doi:10.1016/j.humimm. ...
In 2015 cardiomyopathy, including myocarditis, resulted in 354,000 deaths up from 294,000 in 1990. The initial descriptions of ... Worldwide, however, the most common cause is Chagas disease, an illness endemic to Central and South America that is due to ... Complications may include heart failure due to dilated cardiomyopathy or cardiac arrest. Myocarditis is most often due to a ... 1983.) "Myocarditis - Cardiomyopathy Historic Survey and Definition", International Boehringer Mannheim Symposia, 1:5. Joseph ...
... or told you cant give blood cuz Chagas? call us ipsum doloret no this is not realy latin semper ubi sub ubi yes it... ... The goal of this study is to determine the prevalence of Chagas disease in patients presenting with dilated cardiomyopathy to ... The public health impact of this study is considerable as it will critically impact the clinical understanding of Chagas ...
... Fernando A. Botoni,1,2,3 Antonio Luiz P. Ribeiro,1,2 Carolina Coimbra Marinho,4 Marcia ... Therefore, the objective of this review is to describe the treatment of Chagas cardiomyopathy with emphasis on its ... Despite its importance, chronic chagas cardiomyopathy (CCC) pathophysiology is yet poorly understood, and independently of its ... Chagas disease (ChD), caused by the protozoa Trypanosoma cruzi (T. cruzi), was discovered and described by the Brazilian ...
... Minna M. D. Romano, Henrique T. Moreira, André ... In Chagas disease (CD), there is direct evidence from both basic and clinical research of profound structural RV abnormalities ...
Chagas Cardiomyopathy. Heart Failure. Cardiomyopathies. Heart Diseases. Cardiovascular Diseases. Chagas Disease. ... Chagas Cardiomyopathy Bisoprolol Intervention Study: Charity. The safety and scientific validity of this study is the ... Heart failure due to Chagas cardiomyopathy (CCM) is the main clinical form of CD in Colombia. However, the incidence of CCM ... However, these benefits have not been proven in Chagas´ cardiomyopathy (25,26). Nevertheless, there are reasons to believe that ...
... causing dilated cardiomyopathy and megavisceral disease. Although Chagas disease is the leading cause of heart failure in ... protozoan is able to persist asymptomatically for decades until ultimately causing organ-specific symptoms of chronic Chagas ... is the etiologic agent of the zoonotic Chagas disease that affects approximately six to seven million people in Central and ... 9. The role of STAT proteins in Chagas cardiomyopathy. There is growing evidence that not only NF-kB but also STAT ...
Failure to Diagnose Chagas Cardiomyopathy including overlooked symptoms and complications for under-diagnosed medical ... Undiagnosed Complications of Chagas Cardiomyopathy. As part of Chagas Cardiomyopathy diagnosis, consider whether any of these ... is the failure to correctly diagnose Chagas Cardiomyopathy leading to a person remaining with undiagnosed Chagas Cardiomyopathy ... not necessarily specific to Chagas Cardiomyopathy: *Failure to Diagnose *Under-Diagnosed Diseases *How Common is Failure to ...
Cardiomyopathies. Chagas Cardiomyopathy. Heart Diseases. Cardiovascular Diseases. Chagas Disease. Trypanosomiasis. Euglenozoa ... Chagas disease. Chagas Cardiomyopathy. Trypanosoma cruzi. Omega-3. Cytokines. Lipid profile. Nutritional assessment. ... Effects of Omega-3 Supplementation on the Cytokine and Lipid Profiles in Patients With Chronic Chagas Cardiomyopathy. The ... Chagas Cardiomyopathy Dietary Supplement: Omega-3 Dietary Supplement: Placebo Comparator Early Phase 1 ...
... will manifest Chagas cardiomyopathy (CC). Identification of reliable early indicators of CC risk would enable prioritization of ... f Circulating Serum Markers and QRS Scar Score in Chagas Cardiomyopathy * Eva H. Clark, Morgan A. Marks, Robert H. Gilman, ... Chagas cardiomyopathy in the context of the chronic disease transition. PLoS Negl Trop Dis 4: e688.[Crossref] ... Matrix metalloproteinases 2 and 9 as diagnostic markers in the progression to Chagas cardiomyopathy. Am Heart J 165: 558-566.[ ...
Temporal trends in the contribution of Chagas cardiomyopathy to mortality among patients with heart failure ... Temporal trends in the contribution of Chagas cardiomyopathy to mortality among patients with heart failure ... Temporal trends in the contribution of Chagas cardiomyopathy to mortality among patients with heart failure ...
Chronic Chagas cardiomyopathy: a therapeutic challenge and future strategies Juan D. Maya; Juan D. Maya ... pages 579-584) discuss therapeutic strategies in chronic Chagas cardiomyopathy, which is caused by T. cruzi. In addition, ... Chagas cardiomyopathy presents several vascular characteristics that are similar to those presented in other acquired ... Chronic Chagas cardiomyopathy: a therapeutic challenge and future strategies. Emerg Top Life Sci 22 December 2017; 1 (6): 579- ...
Purpose of Review Chagas cardiomyopathy is an emerging form of non-ischemic cardiomyopathy in the USA. This review aims to ... Chagas cardiomyopathy is an emerging form of non-ischemic cardiomyopathy in the USA. This review aims to summarize current ... The incidence of Chagas cardiomyopathy is increasing in the USA, driven mainly by immigration from countries where Chagas ... Chagas cardiomyopathy Trypanosoma cruzi Myocarditis Trypanocidal therapy Heart transplantation Reactivation This article is ...
Abstract Spasm and thrombosis of the coronary microcirculation has been implicated in the pathogenesis of the cardiomyopathy of ... Chagas' disease. We demonstrate that increases in platelet adherence and aggregation accompany Trypanosoma cruzi infection ... support the hypothesis that heightened platelet reactivity and endothelial cell dysfunction are associated with acute Chagas& ... Enhanced Platelet Adherence and Aggregation in Chagas' Disease: A Potential Pathogenic Mechanism for Cardiomyopathy * ...
Objective: To determine whether T cruzi DNA detected by PCR is associated with progression to chronic Chagas cardiomyopathy. ... Risk progression to chronic Chagas cardiomyopathy: influence of male sex and of parasitaemia detected by polymerase chain ... Risk progression to chronic Chagas cardiomyopathy: influence of male sex and of parasitaemia detected by polymerase chain ... Progression to cardiomyopathy was detected in 12 patients (21.4%). Three of these patients died after baseline evaluation. ...
Pathology and Pathogenesis of Chagas Heart Disease.. Abstract Chagas heart disease is an inflammatory cardiomyopathy that ... More News: Allergy & Immunology , Cardiology , Cardiomyopathy , Chagas Disease , Genetics , Heart , Heart Disease , Parasitic ... Betulinic Acid Derivative BA5, Attenuates Inflammation and Fibrosis in Experimental Chronic Chagas Disease Cardiomyopathy by ... Mariana Caldas Waghabi TGF-β involvement in Chagas disease cardiomyopathy has been clearly demonstrated. The TGF-β signaling ...
We congratulate the authors for this comprehensive review of Chagas cardiomyopathy, which is one of the most important ... 1999) Time to first shock in implantable cardioverter defibrillator (ICD) patients with Chagas cardiomyopathy. Pacing Clin ... Catheter Ablation to Treat Sustained Ventricular Tachycardia in Patients With Chagas Cardiomyopathy and Implantable ... Catheter Ablation to Treat Sustained Ventricular Tachycardia in Patients With Chagas Cardiomyopathy and Implantable ...
Heart failure due to Chagas cardiomyopathy is the main clinical presenation in Colombia. Heart failure due to Chagas disease ... Home » CHARITY: Chagas cardiomyopathy bisoprolol intervention study: a randomized double-blind placebo force-titration ... CHARITY: Chagas cardiomyopathy bisoprolol intervention study: a randomized double-blind placebo force-titration controlled ... This study will allow us to explore the effect of beta-blockers in chagas cardiomyopathy. ...
Diagnostic Value of NT-proBNP for Early Identification of Chagas Cardiomyopathy in Non-endemic Areas. ...
Patients with chronic Chagas disease presented a negative correlation between left ventricular ejection fraction (LVEF) and the ... Samples from uninfected health individuals (CONT, n = 30) and patients with ischaemic cardiomyopathy (ISCH, n = 15) were used ... production and their possible association with different clinical forms of human chronic Chagas disease. METHODS IgG total and ... autoantibodies probably influences the left ventricular ejection fraction and could be related to chagasic cardiomyopathy. ...
Key words: Chagas disease, Chagas cardiomyopathy, Trypanosoma cruzi, electrocardiography, seroepidemiologic studies, Mexico. ... Chagas cardiomyopathy and serologic testing in a small rural hospital in Chiapas, Mexico ... Suggested citation Capps L, Abad B. Chagas cardiomyopathy and serologic testing in a small rural hospital in Chiapas, Mexico. ... Chagas cardiomyopathy and serologic testing in a small rural hospital in Chiapas, Mexico ...
Diagnostic Tests for Chagas Cardiomyopathy including blood tests, urine tests, swabs, diagnostic tests, lab tests, and ... Symptoms of Chagas Cardiomyopathy *Home Diagnostic Testing *Complications Home Diagnostic Testing. These home medical tests may ... be relevant to Chagas Cardiomyopathy: *High Blood Pressure: Home Testing *Home Blood Pressure Hypertension Tests *Home Blood ... Diagnostic Tests for Chagas Cardiomyopathy. *Home Diagnostic Testing for Chagas Cardiomyopathy. *Signs of Chagas Cardiomyopathy ...
title = "Chagas cardiomyopathy in the context of the chronic disease transition",. abstract = "Background: Patients with Chagas ... Chagas cardiomyopathy in the context of the chronic disease transition. Together they form a unique fingerprint. * Chagas ... Chagas cardiomyopathy in the context of the chronic disease transition. Alicia I. Hidron, Robert H. Gilman, Juan Justiniano, ... Chagas cardiomyopathy in the context of the chronic disease transition. / Hidron, Alicia I.; Gilman, Robert H.; Justiniano, ...
Patients with Chagas cardiomyopathy who had a previous CMR evaluation were included, and clinical follow-up was retrospectively ... MF is an independent predictor of adverse outcome in Chagas cardiomyopathy. Our data may support the use of CMR in better risk- ... Myocardial fibrosis (MF) according to cardiac magnetic resonance (CMR) is a frequent finding in Chagas cardiomyopathy and has ... Long-Term Prognostic Value of Myocardial Fibrosis in Patients With Chagas Cardiomyopathy. ...
Blood Gene Signatures of Chagas Cardiomyopathy With or Without Ventricular Dysfunction. Blood Gene Signatures of Chagas ... About 30% of infected patients will develop chronic Chagas cardiomyopathy (CCC), an inflammatory cardiomyopathy characterized ... Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, affects 7 million people in Latin American areas of ... NK/CD8+ T-cell cytotoxicity could play a role in determining Chagas disease progression. Understanding genes associated with ...
Chronic Chagas cardiomyopathy: a therapeutic challenge and future strategies. Juan D. Maya, Michel Lapier, Christian Castillo, ... Chronic Chagas cardiomyopathy: a therapeutic challenge and future strategies. Juan D. Maya, Michel Lapier, Christian Castillo, ... Chronic Chagas cardiomyopathy: a therapeutic challenge and future strategies Message Subject (Your Name) has forwarded a page ... Chagas cardiomyopathy presents several vascular characteristics that are similar to those presented in other acquired ...
Dilated cardiomyopathy is a progressive disease of heart muscle that is characterized by ventricular chamber enlargement and ... Chagas cardiomyopathy. Chagas disease caused by Trypanosoma cruzi. The acute presentation is characterized by dyspnea, fever, ... hypertensive cardiomyopathy, tachycardia-induced cardiomyopathy, Takotsubo cardiomyopathy, or ischemic cardiomyopathy after ... Chagas cardiomyopathy in New Orleans and the Southeastern United States. Ochsner J. 2016 Fall. 16(3):304-8. [Medline]. ...
... Authors: George A. Mensah , Center for Translation Research and ... Mensah, G. A., et al.. "Opportunities and Challenges in Chronic Chagas Cardiomyopathy". Global Heart, vol. 10, no. 3, 2015, pp ... Opportunities and Challenges in Chronic Chagas Cardiomyopathy. Global Heart, 10(3), pp.203-207. DOI: http://doi.org/10.1016/j. ... "Opportunities and Challenges in Chronic Chagas Cardiomyopathy". Global Heart 10 (3): 203-7. DOI: http://doi.org/10.1016/j. ...
Immunopathology of cardiomyopathy in the experimental Chagas disease Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. ... Immunopathology of cardiomyopathy in the experimental Chagas disease. Memórias do Instituto Oswaldo Cruz, Rio de Janeiro, v. 94 ... Immunopathology of cardiomyopathy in the experimental Chagas disease. by: Soares, Milena Botelho Pereira Published: (1999) ... Immunopathology of Chagas disease by: Andrade, Zilton de Araújo Published: (1999) * Immunopathology of Chagas disease by: ...
Cardiomyopathy, Chagas; Trypanosomiasis, Cardiovascular; Myocarditis, Chagas. On-line free medical diagnosis assistant. Ranked ... We suspected chronic Chagas heart disease, i.e., dilated cardiomyopathy with apical ventricular aneurysm, right bundle branch ... A 56-year-old man underwent orthotopic heart transplantation because of end-stage Chagas cardiomyopathy. One hundred and ten ... Reactivation of cardiac Chagas disease in acquired immune deficiency syndrome. We report the case of a 29-year-old man who ...
5.2.4. Chagas cardiomyopathy. Chagas disease, caused by Trypanosoma cruzi (T. cruzi), affects ~10 million people per year, ... Of those affected, many have no long-term sequelae but up to 40% can develop Chagas Cardiomyopathy with arrhythmias, heart ... 5.2.2. Dilated cardiomyopathy. Dilated cardiomyopathy (DCM) is a progressive disease that is a major cause of heart failure ... The vast majority of patients with Chagas cardiomyopathy are known to possess IgG autoantibodies suggesting an autoimmune ...
chronic Chagas cardiomyopathy. CPC. cardiac progenitor cell. DAB. [1,1′-biphenyl]-3,3′,4,4′-tetramine. ECG. electrocardiogram. ... In chronic Chagas cardiomyopathy, T. cruzi burden is so low that it is difficult to detect by optical microscopy (Fig. 3A). ... Chronic Chagas Cardiomyopathy Mouse Model.. We used the mouse model of CCC described earlier by the Ribeiro-dos Santos group ( ... 2017) Chronic Chagas heart disease management: from etiology to cardiomyopathy treatment. J Am Coll Cardiol 70:1510-1524. ...
  • Chagas' disease (ChD), caused by the protozoa Trypanosoma cruzi ( T. cruzi ), was discovered and described by the Brazilian physician Carlos Chagas in 1909. (hindawi.com)
  • The protozoan hemoflagellate Trypanosoma cruzi (T. cruzi) is the etiologic agent of the zoonotic Chagas' disease that affects approximately six to seven million people in Central and South America, causing dilated cardiomyopathy and megavisceral disease. (intechopen.com)
  • The pathogenic protozoan Trypanosoma cruzi ( T. cruzi ) is the causative agent of Chagas' disease, and more than 150 species of mammals are affected by this unicellular parasite, including humans. (intechopen.com)
  • Approximately 8 million people have Trypanosoma cruzi infection, and nearly 30% will manifest Chagas cardiomyopathy (CC). Identification of reliable early indicators of CC risk would enable prioritization of treatment to those with the highest probability of future disease. (ajtmh.org)
  • Trypanosoma cruzi and Chagas' disease in the United States. (springer.com)
  • The United States Trypanosoma cruzi Infection Study: evidence for vector-borne transmission of the parasite that causes Chagas disease among United States blood donors. (springer.com)
  • Polymerase chain reaction (PCR) allows detection of Trypanosoma cruzi in blood throughout the course of Chagas' disease. (bmj.com)
  • Abstract The infection with the protozoan parasite Trypanosoma cruzi causes Chagas disease, a neglected tropical disease in Latin America and an imported emerging disease worldwide. (medworm.com)
  • Introduction Chagas disease, also known as American trypanosomiasis, is a neglected parasitic disease caused by the protozoan Trypanosoma cruzi (1), that affects millions of people in the world (2). (medworm.com)
  • OBJECTIVE To evaluate the potential involvement of anti-Trypanosoma cruzi and cardiac protein antibody (IgG total and isotypes) production and their possible association with different clinical forms of human chronic Chagas disease. (semanticscholar.org)
  • Chagas disease , caused by the protozoan parasite Trypanosoma cruzi , affects 7 million people in Latin American areas of endemicity. (bvsalud.org)
  • The mechanisms by which Trypanosoma cruzi causes cardiomyopathy and induces neuronal destruction are discussed in this paper. (ibict.br)
  • The diagnosis of chronic Chagas' disease was finally confirmed by the demonstration of trypanosoma cruzi itself in the blood as well as trypanosoma cruzi antibodies . (lookfordiagnosis.com)
  • Analysis of the presence of trypanosoma cruzi in the heart tissue of three patients with chronic Chagas' heart disease. (lookfordiagnosis.com)
  • Trypanosoma cruzi is the causative agent of incurable Chagas disease, which is endemic in Latin America and estimated by the Centers for Disease Control and Prevention to afflict more than 8 million people worldwide ( www.CDC.gov ). (aspetjournals.org)
  • Infection with Trypanosoma cruzi, the etiologic agent in Chagas disease, may result in heart disease. (elsevier.com)
  • Genome wide association study (GWAS) of Chagas cardiomyopathy in Trypanosoma cruzi seropositive subjects. (cdc.gov)
  • Chagas disease is caused by Trypanosoma cruzi which is endemic in Latin America. (elsevier.com)
  • The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. (medscape.com)
  • Only a subset of individuals infected with Trypanosoma cruzi develop chronic Chagas cardiomyopathy (CCC). (oup.com)
  • Chagas disease caused by the protozoan parasite Trypanosoma cruzi represents a significant public health problem in Latin America, affecting around 8 million cases worldwide. (bioportfolio.com)
  • Quantification of Immunoglobulin G against Trypanosoma cruzi in Individuals with Chronic Chagas Disease Treated with Nifurtimox and Evaluated in Prolonged Follow-Up. (bioportfolio.com)
  • Chronic cardiomyopathy is the main clinical manifestation of Chagas disease (CD), a disease caused by Trypanosoma cruzi infection. (frontiersin.org)
  • Chagas' disease is caused by a protozoan parasite, Trypanosoma cruzi, that is transmitted to humans through the feces of infected bloodsucking insects in endemic areas of Latin America, or occasionally by nonvectorial mechanisms, such as blood transfusion. (medicalcriteria.com)
  • Chagas disease , also known as American trypanosomiasis , is a tropical parasitic disease caused by the protist Trypanosoma cruzi . (wikipedia.org)
  • An outbreak of Chagas disease in a low-income district of urban Belém, in September 2000, affected 11 people simultaneously, indicating the likelihood of indirect, oral transmission of Trypanosoma cruzi. (scielosp.org)
  • Chagas cardiomyopathy is caused by Trypanosoma cruzi ( Tc ). (frontiersin.org)
  • Chagas cardiomyopathy, caused by Trypanosoma cruzi , is a major health concern in Latin America and it is an emerging disease in the United States, Europe, Japan, and other countries ( 1 ). (frontiersin.org)
  • Chagas disease, caused by Trypanosoma cruzi parasite, is one of the most prevalent parasitic infections in Latin America and is responsible for millions of clinical cases. (cdc.gov)
  • Infection by Trypanosoma cruzi (Chagas disease [ChD]) affects around 7 million people in the Americas, most of whom are unaware of their status due to lack of clinical manifestations and poor access to diagnosis. (asm.org)
  • Infection by Trypanosoma cruzi , or Chagas disease (ChD), affects around 6 to 8 million people in the Americas ( 1 ). (asm.org)
  • In 2017, a blood donation in Missouri screened positive for antibodies to Trypanosoma cruzi , the parasite that causes Chagas disease. (cdc.gov)
  • The patient had donated blood, and laboratory screening revealed antibodies to Trypanosoma cruzi , the parasite that causes Chagas disease. (cdc.gov)
  • Towards the establishment of a consensus real-time qPCR to monitor Trypanosoma cruzi parasitemia in patients with chronic Chagas disease cardiomyopathy: a substudy from the BENEFIT trial. (curehunter.com)
  • Chronic chagasic cardiomyopathy, which is caused by the protozoan Trypanosoma cruzi, is a major cause of heart failure in Latin America. (ebscohost.com)
  • Trypanosoma cruzi P21: a potential novel target for chagasic cardiomyopathy therapy. (ebscohost.com)
  • Chagas disease, which is caused by the parasite Trypanosoma cruzi, is an important cause of cardiomyopathy in Latin America. (ebscohost.com)
  • A study was conducted to determine the prevalence of positive serology for Trypanosoma cruzi in patients with clinical diagnosis of dilated cardiomyopathy. (ebscohost.com)
  • Chagas disease is caused by the parasite Trypanosoma cruzi transmitted by triatomine vectors of the subfamily Reduviidae. (renalandurologynews.com)
  • Trypanosoma cruzi , el agente causal de la enfermedad de Chagas, tiene la capacidad de infectar m ltiples tejidos, incluidos los islotes de Langerhans y el tejido adiposo. (medigraphic.com)
  • Detection of Trypanosoma cruzi DNA in blood by PCR is associated with Chagas cardiomyopathy and disease severity. (nih.gov)
  • Chagas disease, a neglected disease caused by Trypanosoma cruzi , remains a serious public health problem and affects about 10 million people in Latin America [ 1 ]. (biomedcentral.com)
  • La enfermedad de Chagas es una infeccion causada por el parasito protozoario Trypanosoma cruzi , un microorganismo endemico en America Latina y transmitido por vectores de diversas especies de la subfamilia Triatominae. (thefreedictionary.com)
  • Up to 50 years with chronic Trypanosoma cruzi infection without advanced Chagas cardiomyopathy: Treatment is strongly recommended. (drugs.com)
  • Chagas disease, or American trypanosomiasi s, is a tropical parasitic disease caused by the flagellate protozoan Trypanosoma cruzi (T. cruzi) . (paho.org)
  • Sustained rapid ventricular tachycardia (VT) is recognized as the most important cause of sudden cardiac death in Chagas disease. (onlinejacc.org)
  • Background: Patients with Chagas disease have migrated to cities, where obesity, hypertension and other cardiac risk factors are common. (elsevier.com)
  • Myocardial fibrosis (MF) according to cardiac magnetic resonance (CMR) is a frequent finding in Chagas cardiomyopathy and has been associated with risk factors of poor outcome. (bvsalud.org)
  • To account for the contrast between cardiac regeneration in high-parasitism acute infection and progressive cardiomyopathy in low-parasitism CCC, we hypothesized that T. cruzi expresses repair factors that directly facilitate cardiac regeneration. (aspetjournals.org)
  • Using in vivo and in vitro models of Chagas disease, we tested whether T. cruzi PDNF promotes cardiac repair. (aspetjournals.org)
  • Our findings are in support of the novel concept that T. cruzi uses PDNF to promote mutually beneficial cardiac repair in Chagas disease. (aspetjournals.org)
  • Chagas' cardiomyopathy is a complication of Chagas' disease that presents in the cardiac form, which involves the manifestation of a clinical picture of dilated cardiomyopathy, with global left ventricular dysfunction and heart failure syndrome. (who.int)
  • Human platelet antigen (HPA) polymorphisms are considered to be a risk factor for cardiac and vascular diseases, but the role of HPA in chronic Chagas disease cardiomyopathy (CCC) is not available. (cdc.gov)
  • Our results show that HFD perturbs lipid metabolism and induces oxidative stress to exacerbate late chronic Chagas disease cardiac pathology. (elsevier.com)
  • Familial aggregation of Chagas cardiac disease in T. cruzi-infected persons suggests that human genetic variation may be an important determinant of disease progression. (cdc.gov)
  • Other than history, the only potentially distinguishing feature between IDC and alcohol cardiomyopathy is that the latter may present with a relatively high cardiac output. (rjmatthewsmd.com)
  • National programs have historically only treated children with Chagas disease, but the impetus for adult treatment has grown significantly in the last 10 years, based on growing patient demand and observational data suggesting that treatment, even in patients with early cardiac morbidity decreases the progression of Chagas heart disease and possibly also mortality. (ucsf.edu)
  • Biomarkers to detect early Chagas heart disease may reflect early changes in cardiac structure and function, substances such as B-type natriuretic peptide released in response to cardiac disease or a substance such as transforming growth factor- beta1 involved in cardiac pathogenesis at the cellular level. (ucsf.edu)
  • Cardiac gene expression profiling provides evidence for cytokinopathy as a molecular mechanism in Chagas' disease cardiomyopathy. (duke.edu)
  • Our outcomes claim that mitochondrial transportation of PARP1 adversely influences the mtDNA maintenance by Pol replisome, and exacerbates the mitochondrial dysfunction, oxidative tension, and cardiac redecorating in Chagas disease. (az628.com)
  • The purpose of this study is to determine if 60 days of treatment with an antiparasitic drug (benznidazole) could prevent the progression of cardiac disease in patients with Chagas disease. (bioportfolio.com)
  • Patients with clinically manifest cardiac or gastrointestinal Chagas disease should be managed by appropriate specialists (see Consultations). (medscape.com)
  • Cardiac morbidity and mortality due to Chagas' disease: prospective electrocardiographic study of a Brazilian community. (biomedsearch.com)
  • Cardiac, neuronal, and muscle electrical signaling is controlled and modulated by changes in voltage-gated ion channel activity that occur through physiological and pathological processes such as development, epilepsy, and cardiomyopathy. (pnas.org)
  • Clinical management of patients with chronic Chagas disease begins with proper clinical stratification and the identification of individuals at a higher risk of sudden cardiac death. (scielo.br)
  • In ~30% of the infected individuals, clinical symptoms progress from cardiac hypertrophic remodeling (i.e., wall thickening) to dilated cardiomyopathy, and ultimately result in cardiac arrest and death ( 2 ). (frontiersin.org)
  • The cardiomyopathy is a disease in the cardiac muscle that can be classified according with the structural and functional abnormalities of the cardiac muscle, such as: dilated, hypertrophic, restrictive, arrithmogenic and non-classified cardiomyopathy. (fac.org.ar)
  • Chronic Chagas disease presents different clinical manifestations ranging from asymptomatic (namely indeterminate) to severe cardiac and/or digestive. (biomedcentral.com)
  • The Batista procedure was invented by Brazilian physician and cardiac surgeon Randas Batista in 1994 for use in patients with non-ischemic dilated cardiomyopathy. (wikipedia.org)
  • Increased frequencies of circulating CCR5+ memory T cells are correlated to chronic chagasic cardiomyopathy progression. (medworm.com)
  • Chronic Chagasic cardiomyopathy (CCC), a progressive inflammatory and fibrosing disease, is the most prominent clinical form of Chagas disease, culminating in heart failure and high rates of sudden death. (medworm.com)
  • To conduct a study in a small rural hospital located in the state of Chiapas, Mexico, to: (1) examine the prevalence of chagasic cardiomyopathy among patients with the diagnosis of congestive heart failure and (2) assess the prevalence of positive serologic results in blood donors in the hospital, in an attempt to ascertain whether Chagas' disease remains an important cause of heart failure at least in some areas of Mexico. (scielosp.org)
  • Modulation of chagasic cardiomyopathy by interleukin-4: dissociation between inflammation and tissue parasitism. (ibict.br)
  • In this context, the aim is to describe the Nursing Diagnosis evidenced in the literature in patients with Chagasic Cardiomyopathy. (who.int)
  • Chagasic cardiomyopathy is normally due to infection. (az628.com)
  • These research demonstrate pathologic need for mtROS in chagasic cardiomyopathy. (az628.com)
  • A hallmark of chronic chagasic cardiomyopathy (CCC) is a fibrogenic inflammation mainly composed of CD8 + and CD4 + T cells and macrophages. (frontiersin.org)
  • It is estimated that 10%-30% of all infected individuals will acquire chronic chagasic cardiomyopathy (CCC). (ebscohost.com)
  • We have previously shown that clomipramine and allopurinol used separately are effective in preventing chronic chagasic cardiomyopathy. (ebscohost.com)
  • Mitochondrial involvement in chronic chagasic cardiomyopathy. (ebscohost.com)
  • Chagas disease (CD) is the major cause of disability secondary to tropical diseases in young adults from Latin America. (clinicaltrials.gov)
  • Although Chagas' disease is the leading cause of heart failure in Latin America among people living in poverty and places an immense socioeconomic burden on society, it is still currently classified as a neglected tropical disease (NTD). (intechopen.com)
  • Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. (springer.com)
  • (1) . We congratulate the authors for this comprehensive review of Chagas cardiomyopathy, which is one of the most important cardiovascular problems in Latin America and also an emerging disease in nonendemic countries. (onlinejacc.org)
  • Background: Chagas' disease is the major cause of disability secondary to tropical diseases in young adults from Latin America, and around 20 million people are currently infected by T. cruzi. (ebscohost.com)
  • Chagas' disease occurs throughout Latin America and remains a major public health concern in many areas. (scielosp.org)
  • Over the last decades, Chagas disease endemic areas in Latin America have seen a dietary transition from the traditional regional diet to a Western style, fat rich diet. (elsevier.com)
  • Chronic Chagas' disease cardiomyopathy is a leading cause of congestive heart failure in Latin America, affecting more than 3 million people. (duke.edu)
  • Chronic Chagas cardiomyopathy (CCM) is a parasitic disease prevalent in Latin America. (elsevier.com)
  • Chagas disease (CD) is a serious public health problem in Latin America and its treatment remains neglected. (bioportfolio.com)
  • The clinical trial will assess the efficacy and safety of Entresto vs. enalapril and is expected to start within 2019, with the aim of recruiting approximately 900 patients with confirmed Chagas disease in Latin America. (novartis.com)
  • Chagas disease or American trypanosomiasis is a major public health problem in Latin America. (springer.com)
  • Despite efforts to eliminate American trypanosomiasis (Chagas disease) through vector control, the disease continues to be a public health problem in Latin America. (scielosp.org)
  • Chagas heart disease (ChHD) data were reviewed to guide management planning of this disease, which is endemic in Latin America and is becoming a worldwide health burden due to migration (1,2) . (onlinejacc.org)
  • Chagas disease is a major medical and social problem in Latin America and affects 8-10 million people. (scielo.br)
  • Although most documented cases are among persons originally from Latin America, health care providers and public health professionals should be aware of the possibility of locally acquired Chagas disease in the southern United States. (cdc.gov)
  • Chagas disease is the main cause of infectious heart disease in Latin America. (eurekalert.org)
  • Chagas disease is a parasitic disease endemic to Latin America that, if left untreated, can lead to severe long-term organ damage, particularly in the heart and gastrointestinal tract. (springer.com)
  • Chagas disease is the most prevalent communicable tropical disease in Latin America. (paho.org)
  • The goal of this study is to determine the prevalence of Chagas disease in patients presenting with dilated cardiomyopathy to three large acute care hospitals in Houston to assess the clinical impact of this infection and risk factors for acquiring the disease. (bcm.edu)
  • The public health impact of this study is considerable as it will critically impact the clinical understanding of Chagas disease on cardiovascular health in Texas, with an opportunity to identify high risk populations to target for prevention and intervention efforts. (bcm.edu)
  • Despite its importance, chronic chagas cardiomyopathy (CCC) pathophysiology is yet poorly understood, and independently of its social, clinical, and epidemiological importance, the therapeutic approach of CCC is still transposed from the knowledge acquired from other cardiomyopathies. (hindawi.com)
  • In Chagas disease (CD), there is direct evidence from both basic and clinical research of profound structural RV abnormalities. (hindawi.com)
  • Heart failure due to Chagas cardiomyopathy (CCM) is the main clinical form of CD in Colombia. (clinicaltrials.gov)
  • Besides the poor prognosis of CHF due to Chagas disease, it is important to estimate the risk of complications and death in patient infected with T. cruzi Unfortunately, few clinical studies have addressed this issue. (clinicaltrials.gov)
  • Current therapy for the Chagas disease is limited, and it is proposed to combine it with other pharmacological strategies that modify critical physiopathological aspects beneficial for the clinical course of the Chagas cardiomyopathy. (portlandpress.com)
  • Conclusions: We suggest some distinct molecular mechanisms for production of IL-1β in innate immune cells from patients with different clinical forms of Chagas disease. (medworm.com)
  • Patients with Chagas cardiomyopathy who had a previous CMR evaluation were included, and clinical follow-up was retrospectively obtained. (bvsalud.org)
  • The diagnosis of Chagas' cardiomyopathy is based on clinical (history, LV function, and electrocardiographic) criteria and a positive serologic test for T. cruzi. (rjmatthewsmd.com)
  • The major clinical manifestation is Chagas cardiomyopathy, characterized by a chronic inflammatory process leading to conduction system abnormalities, ventricular arrhythmias, sinus node dysfunction and progressive dilated cardiomyopathy with congestive heart failure. (ucsf.edu)
  • Andrade MC, Oliveira MDF, Nagao-Dias AT et al (2013) Clinical and serological evolution in chronic Chagas disease patients in a 4-year pharmacotherapy follow-up: a preliminary study. (springer.com)
  • This review of evidence in the diagnosis and management of Chagas disease (ChD) was done to assist clinicians who are caring for patients with ChHD in common clinical scenarios found in everyday practice. (onlinejacc.org)
  • The objective of this study is to discuss the main clinical and epidemiological aspects of ventricular arrhythmias in Chagas disease, the specific workups and treatments for these abnormalities, and the breakthroughs needed to determine a more effective approach to these arrhythmias. (scielo.br)
  • Serologic diagnosis for chronic Chagas disease was performed using 2 ELISA kits (Ortho-Clinical Diagnostics, https://www.orthoclinicaldiagnostics.com ) and BioELISA Chagas (Biokit, https://www.biokit.com ). (cdc.gov)
  • This will be very important to improve access to diagnosis of Chagas and its clinical management as a neglected disease, especially in remote areas with health access barriers. (asm.org)
  • Based on the epidemiologic, clinical, and laboratory data, the reported case likely represents the first documented autochthonous case of Chagas disease in Missouri. (cdc.gov)
  • Evaluation by physicians found no clinical symptoms consistent with Chagas disease. (cdc.gov)
  • Due to emergence of Chagas disease in the Brazilian Amazon, it is important to report unique clinical features in order to improve patients ' outcomes. (medworm.com)
  • The clinical characteristics of chronic Chagas disease relate to the organs affected. (renalandurologynews.com)
  • The disease, the vector, and its clinical features were first described by the Brazilian physician Carlos Chagas (Figure 3). (renalandurologynews.com)
  • Immunoregulatory mechanisms such as apoptosis are important for the control of Chagas disease, possibly affecting the morbidity in chronic clinical forms. (biomedcentral.com)
  • We aimed to further understand the putative role of apoptosis in Chagas disease and its relation to the clinical forms of the disease. (biomedcentral.com)
  • PCR array were used to evaluate the contribution of this mechanism in specific cell populations from patients with different clinical forms of human Chagas disease. (biomedcentral.com)
  • Experimental and clinical treatment of Chagas disease: a review. (springer.com)
  • Chagas disease has two clinical forms or phases: an acute phase and a chronic phase. (paho.org)
  • Chagas diagnosis is always clinical, epidemiological and based on laboratory testing (parasitology and serology). (paho.org)
  • 7 The clinical frequency of cerebrovascular complications in CD has not been previously described, although postmortem studies have shown that 9%-36% of patients with Chagas' cardiomyopathy have evidence of a cerebral infarction. (bmj.com)
  • Chagas' disease, also termed American trypanosomiasis, causes the third largest disease burden of the tropics after malaria and schistosomiasis [ 2 ] and is responsible for higher morbidity and mortality than any other parasitic infection in America [ 3 ]. (intechopen.com)
  • In addition, Novartis is partnering with the World Heart Federation to develop an end-to-end roadmap for addressing Chagas disease. (novartis.com)
  • The incidence of Chagas cardiomyopathy is increasing in the USA, driven mainly by immigration from countries where Chagas disease is endemic. (springer.com)
  • Chagas' disease is an endemic disease in most Latin American countries. (wiley.com)
  • CCM is a common cause of cardiomyopathy in endemic regions and has a poor prognosis compared to other cardiomyopathies. (elsevier.com)
  • In endemic areas of Bolivia, school children are screened for the program of Chagas disease eradication of the Ministry of Health, an. (bioportfolio.com)
  • At the same time, Novartis is working with stakeholders in endemic countries to co-develop tailored access-to-medicine programs and health system strengthening strategies to help ensure lower-income patients suffering from chronic Chagas cardiomyopathy can benefit from the best available treatment. (novartis.com)
  • Chagas disease is emerging in countries to which it is not endemic. (cdc.gov)
  • Chronic Chagas disease should be suspected in any patient with a history of potential exposure such as living or traveling to endemic areas and who presents with manifestations such as idiopathic cardiomyopathy, arrhythmias, esophageal dysmotility, or megacolon. (renalandurologynews.com)
  • Heart failure secondary to Chagas disease: an emerging problem in non-endemic areas. (medigraphic.com)
  • Schmunis GA. Epidemiology of Chagas disease in non-endemic countries: the role of international migration. (springer.com)
  • Considered a neglected tropical disease or disease of poverty, Chagas is endemic in 21 countries of the Americas. (paho.org)
  • Only benznidazole (Bnz) (1) and nifurtimox (Nfx) (2) are licensed for the treatment of Chagas disease although their safety and efficacy profile are far from ideal. (bioportfolio.com)
  • The investigators propose the evaluation of posaconazole and benznidazole in humans for the treatment of Chagas disease chronical infection. (bioportfolio.com)
  • Despite the efforts to develop new drugs, only two nitroheterocyclic drugs (nifurtimox and benznidazole) are available for the treatment of Chagas disease, These drugs have been available since the 1970s, and no new drugs have been approved. (springer.com)
  • Apt W. Current and developing therapeutic agents in the treatment of Chagas disease. (springer.com)
  • By contrast, in patients whose disease progresses to chronic infection, irreversible degenerative chronic Chagas cardiomyopathy (CCC) may develop. (aspetjournals.org)
  • Future studies should also include exposed seronegative controls to investigate genetic associations with susceptibility or resistance to T. cruzi infection and non-Chagas cardiomyopathy. (cdc.gov)
  • The natural history consists of an initial myocarditis most commonly presenting in childhood, associated with acute myocardial infection followed by recovery and in some individuals the development of a dilated cardiomyopathy 10 to 30 years later. (rjmatthewsmd.com)
  • In the acute phase, the diagnosis of Chagas' disease is made by visualization of parasites on thick and thin blood smears stained with Giemsa, but parasites become difficult to detect by 3 months after the infection. (rjmatthewsmd.com)
  • Because of the extraordinarily high prevalence of infection, this population will be ideal for assessing associations between biomarkers and early Chagas cardiomyopathy. (ucsf.edu)
  • T. cruzi infection results in a latent infection with approximately a third of latently infected patients developing chronic Chagas cardiomyopathy (CCM). (elsevier.com)
  • Our data provide new insights into the metabolic changes that may predispose patients to CCM and biomarkers that may help predict the risk of developing cardiomyopathy from T. cruzi infection. (elsevier.com)
  • The critical element in controlling congenital Chagas disease, beyond reducing the prevalence of chronic T cruzi infection in women of childbearing age, is the thorough parasitologic and serologic evaluation of babies born to mothers with T cruzi infection. (medscape.com)
  • An acute Chagas disease infection with swelling of the right eye (Romaña's sign). (wikipedia.org)
  • Several biomarkers have been reported in Chagas heart disease (ChHD), but most are nonspecific for T. cruzi infection. (onlinejacc.org)
  • Based on published seroprevalence in Latin American immigrant populations (1.31%), it was estimated that approximately 300,000 individuals with T. cruzi infection live in the United States, with 30,000 to 45,000 cardiomyopathy cases and 63 to 315 congenital infections annually (9) . (onlinejacc.org)
  • Given the potential for T. cruzi infection to cause cardiomyopathy, an electrocardiogram was obtained, which showed arrhythmias, including primary atrioventricular block with prolonged PR interval (increased time between the beginning of the P wave and the start of the QRS complex). (cdc.gov)
  • There are many conditions and diseases that cause dilated cardiomyopathy, including the excessive alcohol ingestion, pregnancy, viral infection and the Chagas disease. (fac.org.ar)
  • Chagas disease (also called American trypanosomiasis ) is an infection caused by a parasite common to the areas of South America, Central America and Mexico. (drugs.com)
  • As the prevalence of Chagas cardiomyopathy increases in the USA, practitioners must be aware of the unique challenges in diagnosis and management that Chagas cardiomyopathy presents. (springer.com)
  • The study of patients with cardiomyopathy was conducted by retrospective chart review of patients with the diagnosis of congestive heart failure treated at the hospital during the years 2000-2002. (scielosp.org)
  • Evaluation of adult chronic Chagas' heart disease diagnosis by molecular and serological methods. (medscape.com)
  • Today marks another milestone in our longstanding commitment to the fight against neglected tropical diseases, and we are proud to partner with the Global Chagas Disease Coalition and its members to help improve access to diagnosis and reimagine treatment for people with Chagas disease," said Patrice Matchaba, Group Head, Global Health and Corporate Responsibility at Novartis. (novartis.com)
  • The diagnosis of Chagas can be made during the acute phase of the disease by performing a Giemsa-stained thick or thin blood smear and looking for the trypomastigotes. (renalandurologynews.com)
  • Describe the Nursing diagnosis of the NANDA-I, the interventions of the Nursing Interventions Classification (NIC) and the results of the Nursing Outcomes Classification (NOC) based on a patient with dilated myocardiopathy associated with Chagas disease. (fac.org.ar)
  • For the development of our case study the following steps of the nursing process (NP) were applied: data collection, nursing diagnosis, planning, where the stages of implementation and evaluation are provided as suggestions as the future care of patients with dilated cardiomyopathy related to Chagas disease. (fac.org.ar)
  • Troponin T autoantibodies correlate with chronic cardiomyopathy in human Chagas disease. (semanticscholar.org)
  • Current situation and perspectives regarding human Chagas disease in midwestern of the state of Minas Gerais, Brazil. (medscape.com)
  • Deficient Regulatory T Cell Activity and Low Frequency of IL-17-Producing T Cells Correlate with the Extent of Cardiomyopathy in Human Chagas' Disease. (ebscohost.com)
  • Chronic cardiomyopathy represents the most important and severe manifestation of human Chagas disease, eventually affecting approximately 20-30 % of individuals. (biomedcentral.com)
  • Chagas cardiomyopathy is a chronic, progressive myocarditis, with hallmark features of biventricular dysfunction, ventricular arrhythmias, thromboembolic complications, and a high risk of mortality. (springer.com)
  • As the authors properly described, ventricular arrhythmias are very common in patients with Chagas heart disease, with prevalence and complexity related to the presence and extent of myocardial damage. (onlinejacc.org)
  • We suspected chronic Chagas' heart disease, i.e., dilated cardiomyopathy with apical ventricular aneurysm , right bundle branch block with left anterior fascicular block, and various arrhythmias including supraventricular premature beats, ventricular premature beats and non-sustained ventricular tachycardia because he showed typical echo- and electrocardiographic features of the disease. (lookfordiagnosis.com)
  • Millions afflicted with Chagas disease and other disorders of aberrant glycosylation suffer symptoms consistent with altered electrical signaling such as arrhythmias, decreased neuronal conduction velocity, and hyporeflexia. (pnas.org)
  • Sudden death is one of the most characteristic phenomena of Chagas disease, and approximately one-third of infected patients develop life-threatening heart disease, including malignant ventricular arrhythmias. (scielo.br)
  • Fibrotic lesions secondary to chronic cardiomyopathy produce arrhythmogenic substrates that lead to the appearance and maintenance of ventricular arrhythmias. (scielo.br)
  • Ventricular arrhythmias are important manifestations of Chagas cardiomyopathy. (scielo.br)
  • This review highlights the absence of high-quality evidence regarding the treatment of ventricular arrhythmias in Chagas disease. (scielo.br)
  • Ventricular arrhythmias associated with Chagas heart disease (ChD) have high rates of morbidity and mortality (3) . (scielo.br)
  • Identification of Myocardial Disarray in Patients With Hypertrophic Cardiomyopathy and Ventricular Arrhythmias. (amedeo.com)
  • Individuals with cardiomyopathy may present with a history of heart failure or arrhythmias. (renalandurologynews.com)
  • By electrocardiogram, people with Chagas heart disease most frequently have arrhythmias. (wikipedia.org)
  • About 30% of infected patients will develop chronic Chagas cardiomyopathy (CCC), an inflammatory cardiomyopathy characterized by hypertrophy , fibrosis , and myocarditis . (bvsalud.org)
  • Chagas' disease is discussed as a cause of myocarditis. (rjmatthewsmd.com)
  • Rarely, acute Chagas can result in encephalitis and myocarditis, which can be fatal. (renalandurologynews.com)
  • the combination of vitamin C with benznidazole could be considered as an alternative treatment for Chagas' disease. (greenmedinfo.com)
  • The fecal, oral, and skin microbiota of children with Chagas disease treated with benznidazole. (bioportfolio.com)
  • Benznidazole, itraconazole and their combination in the treatment of acute experimental chagas disease in dogs. (bioportfolio.com)
  • Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease. (bioportfolio.com)
  • Early infections are treatable with the medications benznidazole or nifurtimox, which usually cure the disease if given shortly after the person is infected, but become less effective the longer a person has had Chagas disease. (wikipedia.org)
  • Blood Gene Signatures of Chagas Cardiomyopathy With or Without Ventricular Dysfunction. (bvsalud.org)
  • Dilated cardiomyopathy is a progressive disease of heart muscle that is characterized by ventricular chamber enlargement and contractile dysfunction. (medscape.com)
  • Cardiomyopathy represents a group of diseases of the heart, which involve the heart muscle itself resulting in contractile and relaxation dysfunction of both ventricles leading to progressive chamber dilatation and then hypocontractile walls. (rjmatthewsmd.com)
  • Despite significant left ventricular (LV) systolic dysfunction and cardiomegaly , pulmonary congestion does not seem to be a major finding in Chagas' cardiomyopathy (CC). This study sought to identify echocardiographic parameters associated with pulmonary congestion in CC and in dilated cardiomyopathy of other etiologies, such as non-CC (NCC), and to compare pulmonary venous hypertension between the two entities. (bvsalud.org)
  • Left ventricle (LV) diastolic dysfunction (61.47%), LV systolic dysfunction (51.18%), congestive cardiomyopathy (29.92%), and apical aneurysm (15.74%) were the most frequent echocardiographic findings. (bmj.com)
  • However, over decades with chronic Chagas disease, 30-40% of people develop organ dysfunction (determinate chronic Chagas disease), which most often affects the heart or digestive system. (wikipedia.org)
  • The parasite was discovered in 1909 by the Brazilian physician Carlos Chagas, while dissecting assassin bugs ( Reduviidae ) from the subfamily Triatominae that act as vectors and hosts for the parasite, and was later named after Chagas' scientific mentor Oswaldo Cruz [ 1 ]. (intechopen.com)
  • [12] The disease was first described in 1909 by the Brazilian physician Carlos Chagas , after whom it is named. (wikipedia.org)
  • It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. (curehunter.com)
  • Overall one year mortality in patients with CHF due to Chagas disease has been reported as 34 percent. (clinicaltrials.gov)
  • The event rate we have used to estimate sample size is similar to the expected two-year mortality in patients with CHF due to Chagas disease in NYHA functional class II. (clinicaltrials.gov)
  • So, it is not surprising that a similar observation applies to patients with Chagas VT and frequent ICD discharges that have shown a high total mortality rate when their defibrillators are conventionally programmed (5,6) . (onlinejacc.org)
  • The aim of this study is to evaluate the effects of the selective beta-adrenergic receptor blocker Bisoprolol on cardiovascular mortality, hospital readmission due to progressive heart failure and functional status in patients with heart failure secondary to Chagas' cardiomyopathy. (ebscohost.com)
  • The risk of mortality in Chagas cardiomyopathy is relatively well assessed by the Rassi score. (elsevier.pt)
  • Most of the morbitity and mortality due to Chagas disease is due to the chronic phase of the illness. (renalandurologynews.com)
  • Prevalence of Chagas disease in the Latin American-born population of Los Angeles. (springer.com)
  • Prevalence and impact of Chagas disease among Latin American immigrants with nonischemic cardiomyopathy in Los Angeles, California. (springer.com)
  • What is the prevalence of Chagas disease (American trypanosomiasis) in the US? (medscape.com)
  • The prevalence of chronic Chagas' heart disease as a cause of dilated cardiomyopathy is unknown in the State of Campeche, Mexico. (ebscohost.com)
  • This review aims to summarize current concepts in pathophysiology, disease transmission, medical therapy, and heart transplantation for patients with chronic Chagas cardiomyopathy. (springer.com)
  • These results highlight the importance of T cruzi in the pathophysiology of chronic cardiomyopathy. (bmj.com)
  • The pathophysiology of alcohol cardiomyopathy is thought to he related to the toxic effects of alcohol, plus in some subjects nutritional components such as thiamine deficiency. (rjmatthewsmd.com)
  • These observations have been largely confirmed in the literature, and are currently recommended for managing specific patients with recurrent VTs, particularly those with Chagas VT and other nonischemic cardiomyopathies (11,12) . (onlinejacc.org)
  • In addition, Chagas' disease is the most common cause of nonischemic cardiomyopathy in South and Central America, with over 10 million people afflicted. (rjmatthewsmd.com)
  • Among patients with prior MI or nonischemic cardiomyopathy, VT is usually due to reentry involving regions of slowed conduction adjacent to scar. (bmj.com)
  • Chagas disease represents a parasitic nonischemic cardiomyopathy targeting parasympathetic inflow to the heart. (wikipedia.org)
  • Long-Term Prognostic Value of Myocardial Fibrosis in Patients With Chagas Cardiomyopathy. (bvsalud.org)
  • We have previously shown that bone marrow mononuclear cell (BMC) transplantation is effective in reducing inflammation and fibrosis in the mouse model of Chagas disease. (ebscohost.com)
  • The aim of this study was to compare the indications for pacemaker implantation, intraoperative measurements, and long-term follow-up of patients with Chagas' cardiomyopathy (ChCM) and ischemic cardiomyopathy (ICM) referred for pacemaker implantation. (wiley.com)
  • We performed laboratory tests ELISA and indirect hemagglutination in three groups of individuals 1) asymptomatic voluntary blood donors , 2) patients hospitalized in the cardiology department and 3) patients with dilated cardiomyopathy . (bvsalud.org)
  • Most chronic infections are asymptomatic, which is referred to as indeterminate chronic Chagas disease. (wikipedia.org)
  • To determine whether T cruzi DNA detected by PCR is associated with progression to chronic Chagas cardiomyopathy. (bmj.com)
  • Progression was defined as death from chronic cardiomyopathy or the presence of a new ECG or left ventricular echocardiographic abnormality at the end of follow up. (bmj.com)
  • NK/ CD8 + T-cell cytotoxicity could play a role in determining Chagas disease progression. (bvsalud.org)
  • This GWAS identified suggestive SNPs that may impact the risk of progression to cardiomyopathy. (cdc.gov)
  • The major outcome measure will be progression of Chagas cardiomyopathy over a 4-year follow-up period. (ucsf.edu)
  • Results indicated an important action of M. nigra tincture on the Chagas disease progression. (greenmedinfo.com)
  • Conclusions: Chagas cardiomyopathy remains an important cause of congestive heart failure in this hospital population, and should be evaluated in the context of the epidemiological transition that has increased risk of obesity, hypertension and chronic cardiovascular disease. (elsevier.com)
  • Llevar a cabo un estudio en un hospital rural pequeño del Estado de Chiapas, México, con el fin de: 1) examinar la prevalencia de miocardiopatía chagásica en pacientes con un diagnóstico de insuficiencia cardíaca congestiva y 2) estimar la prevalencia de positividad serológica en donantes de sangre del hospital, con objeto de determinar si la enfermedad de Chagas sigue siendo una causa importante de insuficiencia cardíaca en algunas partes de México. (scielosp.org)
  • Este estudio se suma a las pruebas ya existentes de que la enfermedad de Chagas sigue siendo una de las principales causas de insuficiencia cardíaca en algunas partes de México y de que sigue habiendo un riesgo de transmisión por transfusión de sangre si la sangre donada no se somete a tamizaje con regularidad. (scielosp.org)
  • El objetivo de este informe es describir los resultados del tratamiento para la enfermedad aguda de Chagas durante un seguimiento de cuatro años en pacientes de la región amazónica de Brasil. (scielosp.org)
  • tres pacientes presentaron alteraciones electrocardiográficas indicadoras de enfermedad crónica de Chagas o de secuelas de la enfermedad aguda. (scielosp.org)
  • Se discute la respuesta satisfactoria al tratamiento y la importancia de los análisis parasitológicos seriados de los pacientes con enfermedad aguda de Chagas. (scielosp.org)
  • La enfermedad de Chagas (tripanosomiasis americana): Nota descriptiva. (medigraphic.com)
  • Quimioterapia de la enfermedad de Chagas. (springer.com)
  • Basel, Switzerland, March 14, 2019 - At the Annual Meeting of the Global Chagas Disease Coalition in Barcelona, Spain, Novartis announced that it is joining the Coalition as a member contributor. (novartis.com)
  • As of 2019[update], new drugs for Chagas disease are under development, and experimental vaccines have been studied in animal models. (wikipedia.org)
  • Chagas disease or American trypanosomiasis is included on the NTDs list. (bioportfolio.com)
  • three patients presented electrocardiogram abnormalities consistent with chronic Chagas disease or sequel of acute disease. (scielosp.org)
  • In many cases the first sign of Chagas heart disease is heart failure, thromboembolism, or chest pain associated with abnormalities in the microvasculature. (wikipedia.org)
  • To address this gap in knowledge, we studied the effect of HFD during indeterminate and chronic stages of Chagas disease in the mouse model. (elsevier.com)
  • In the present study, we analyzed various serum metabolomic biomarkers such as acylcarnitines, amino acids, biogenic amines, glycerophospholipids, and sphingolipids in murine models of CCM, where the mice specifically develop either left or right ventricular cardiomyopathy based on the diets fed during the indeterminate stage in a murine model of Chagas disease. (elsevier.com)
  • In the indeterminate chronic period of Chagas disease (ChD) the treatment has not been conclusive, because the serological negativization requires many years. (bioportfolio.com)
  • Improved left ventricular contraction and energetics in a patient with Chagas' disease undergoing partial left ventriculectomy. (lookfordiagnosis.com)
  • On December 13, 2017, the Missouri Department of Health and Senior Services (MDHSS) was notified of a suspected case of Chagas disease in a Missouri woman. (cdc.gov)
  • It is estimated that 6.2 million people, mostly in Mexico, Central America and South America, have Chagas disease as of 2017, resulting in an estimated 7,900 deaths. (wikipedia.org)
  • Multiple causes of dilated cardiomyopathy exist, one or more of which may be responsible for an individual case of the disease (see Etiology ). (medscape.com)
  • Its prognostic value in heart disease of non-Chagas etiology is well established. (elsevier.pt)
  • In order to rapidly identify Chagas patients with a higher risk to develop CCM, a new set of biomarkers specific to Chagas disease is needed. (elsevier.com)
  • Biomarkers for earlier therapeutic response assessment in patients with chronic Chagas disease are needed. (cdc.gov)
  • We profiled plasma-derived extracellular vesicles from a heart transplant patient with chronic Chagas disease and showed the potential of this approach for discovering such biomarkers. (cdc.gov)
  • pages 579-584 ) discuss therapeutic strategies in chronic Chagas cardiomyopathy, which is caused by T. cruzi . (portlandpress.com)
  • We characterized gene expression profiles of human Chagas' cardiomyopathy and dilated cardiomyopathy to identify selective disease pathways and potential therapeutic targets. (duke.edu)
  • IFN-gamma and other cytokine pathways may thus be novel therapeutic targets in Chagas' cardiomyopathy. (duke.edu)
  • A high-dose CoQ10 supplementation could be a potential adjuvant therapeutic to be considered in propionic acidaemia-related cardiomyopathy. (greenmedinfo.com)
  • Given the wide cellular tropism infecting virtually all nucleated cells, the protozoan is able to persist asymptomatically for decades until ultimately causing organ-specific symptoms of chronic Chagas' disease such as chronic heart failure. (intechopen.com)
  • Samples were collected from 499 T. cruzi seropositive blood donors who had donated between 1996 and 2002, and 101 patients with clinically diagnosed Chagas cardiomyopathy. (cdc.gov)
  • Radiofrequency ablation of sustained ventricular tachycardia related to the mitral isthmus in Chagas' disease. (lookfordiagnosis.com)
  • This case report describes the electrophysiological findings of a 62-year-old patient with chronic Chagas' disease and two distinct morphologies of sustained ventricular tachycardia that involved a mitral isthmus. (lookfordiagnosis.com)
  • During the acute phase, Chagas disease can be diagnosed through parasitological methods, given the large number of parasites circulating in the blood. (paho.org)
  • How is megacolon treated in Chagas disease (American trypanosomiasis)? (medscape.com)
  • In 2009, a 51-year-old patient from Bolivia with a history of chronic Chagas disease, exhibiting severe organ involvement (chronic cardiomyopathy Kuschnir III and megacolon and megaesophagus degree IV) ( 5 ), was admitted to the International Health Department (Hospital Clinic, Barcelona). (cdc.gov)
  • Herein, we report the first case in Colombia of chagasic megacolon with cardiomyopathy associated with the T. cruzi I lineage. (ebscohost.com)
  • Heart transplantation is the only treatment for patients with end-stage Chagas cardiomyopathy, but is associated with unique challenges including risk of reactivation. (springer.com)
  • Dilated cardiomyopathy is the third most common cause of heart failure and the most frequent reason for heart transplantation. (medscape.com)
  • histoplasmosis as a late infectious complication following heart transplantation in a patient with Chagas' disease. (lookfordiagnosis.com)
  • A 43-year-old patient with heart failure , precluded from heart transplantation or dynamic cardiomyoplasty because of Chagas' disease cardiomyopathy, mitral regurgitation, and ventricular mural thrombi, underwent mitral valvuloplasty and partial left ventriculectomy (PLV) between the papillary muscles . (lookfordiagnosis.com)